Gliovascular alterations in sporadic and familial Alzheimer's disease: APOE3 Christchurch homozygote glioprotection

Probably not a substantial claim: may not pass S3 (load-bearing).

Astroglial proliferation has also been related with GFAP upregulation.

“Astroglial proliferation has also been related with GFAP upregulation [71, 91, 110].”

• cites [71] Heneka MT, Sastre M, Dumitrescu‐Ozimek L, Dewachter I, Walter J, Klockgether T, et al. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation. 2005; 2: 1– 12. 16212664 PMC1274341 sourceSupported
• cites [91] Hol EM, Capetanaki Y. Type III intermediate filaments desmin, glial fibrillary acidic protein (GFAP), vimentin, and peripherin. Cold Spring Harb Perspect Biol. 2017; 9(12): 1– 18. PMC5710105 29196434 sourcePartly supported

  Section 3.2.2 (page not available) states that GFAP is upregulated in reactive astrocytes during gliosis. It does not establish that astroglial proliferation, specifically, is related to that upregulation; reactivity and proliferation are not interchangeable. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [110] Serrano‐Pozo A, Gómez‐Isla T, Growdon JH, Frosch MP, Hyman BT. A phenotypic change but not proliferation underlies glial responses in Alzheimer disease. Am J Pathol. 2013; 182(6): 2332– 44. 23602650 PMC3668030 sourceDisputed

  In “Phenotypic Change But Constant Number of Astrocytes in AD” (page unavailable), the number of GFAP-positive astrocytes increased, but the total number of astrocytes did not differ significantly between patients with AD and controls. The paper attributes increased GFAP immunoreactivity primarily to a change in existing astrocytes, rather than proliferation. (LLM, conf=0.89)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Through GLAST, astroglia dynamically remove glutamate from the extracellular milieu, restricting its signaling activity in time and space and allowing for its recycling.

“Through the membrane glutamate aspartate transporter (GLAST), the astroglia dynamically remove glutamate from the extracellular milieu, restricting its signaling activity in time and space and allowing for its recycling [25, 30, 33].”

• cites [25] Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001; 65(1): 1– 105. 11369436 sourceNot checked — no full text of the source
• cites [30] Roberts RC, Roche JK, McCullumsmith RE. Localization of excitatory amino acid transporters EAAT1 and EAAT2 in human postmortem cortex: a light and electron microscopic study. Neuroscience. 2014; 277: 522– 40. 25064059 PMC4164610 sourceSupported
• cites [33] Armbruster M, Hanson E, Dulla CG. Glutamate clearance is locally modulated by presynaptic neuronal activity in the cerebral cortex. J Neurosci. 2016; 36(40): 10404– 15. 27707974 PMC5050332 sourcePartly supported

  The Introduction (page unavailable) says astrocytic transporters, including GLAST and GLT-1, rapidly remove extracellular glutamate and restrict signaling in time and space. The paper also reports dynamic modulation of clearance, but the cited passages attribute it to EAAT function generally, not specifically to GLAST, and do not address glutamate recycling. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Astroglial cells are the main regulators of cerebral glutamate clearance and metabolism.

“The astroglial cells are the main regulators of cerebral glutamate clearance and metabolism [21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36].”

• cites [21] Walls AB, Waagepetersen HS, Bak LK, Schousboe A, Sonnewald U. The glutamine–glutamate/GABA cycle: function, regional differences in glutamate and GABA production and effects of interference with GABA metabolism. Neurochem Res. 2014; 40(2): 402– 9. 25380696 sourceNot checked — no full text of the source
• cites [22] Tapiero H, Mathé G, Couvreur P, Tew KD II. Glutamine and glutamate. Biomed Pharmacother. 2002; 56(9): 446– 57. 12481981 sourceNot checked — no full text of the source
• cites [23] Hakvoort TBM, He Y, Kulik W, Vermeulen JLM, Duijst S, Ruijter JM, et al. Pivotal role of glutamine synthetase in ammonia detoxification. Hepatology. 2017; 65(1): 281– 93. 27641632 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites [24] Rose CF, Verkhratsky A, Parpura V. Astrocyte glutamine synthetase: pivotal in health and disease. Biochem Soc Trans. 2013; 41(6): 1518– 24. 24256247 sourceNot checked — no full text of the source
• cites [25] Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001; 65(1): 1– 105. 11369436 sourceNot checked — no full text of the source
• cites [26] Murphy‐Royal C, Dupuis JP, Varela JA, Panatier A, Pinson B, Baufreton J, et al. Surface diffusion of astrocytic glutamate transporters shapes synaptic transmission. Nat Neurosci. 2015; 18(2): 219– 26. 25581361 sourceNot checked — no full text of the source
• cites [27] Son H, Kim S, Hyuk JD, Baek JH, Lee DH, Roh GS, et al. Insufficient glutamine synthetase activity during synaptogenesis causes spatial memory impairment in adult mice. Sci Rep. 2019; 9(1): 1– 9. 30670758 PMC6342969 sourceSupported
• cites [28] Verkhratsky A, Ho MS, Vardjan N, Zorec R, Parpura V, Verkhratsky A. General pathophysiology of astroglia HHS public access. Adv Exp Med Biol. 2019; 1175: 149– 79. 31583588 PMC7188602 sourceSupported
• cites [29] Albrecht J, Sidoryk‐Wȩgrzynowicz M, Zielińska M, Aschner M. Roles of glutamine in neurotransmission. Neuron Glia Biol. 2010; 6(4): 263– 76. 22018046 sourceNot checked — no full text of the source
• cites [30] Roberts RC, Roche JK, McCullumsmith RE. Localization of excitatory amino acid transporters EAAT1 and EAAT2 in human postmortem cortex: a light and electron microscopic study. Neuroscience. 2014; 277: 522– 40. 25064059 PMC4164610 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Glutamine can be reconverted into glutamate for use as a neurotransmitter or energy substrate.

“which in turn can be reconverted into glutamate for use either as a neurotransmitter or energy substrate [21, 22, 23, 24, 25, 26, 27].”

• cites [21] Walls AB, Waagepetersen HS, Bak LK, Schousboe A, Sonnewald U. The glutamine–glutamate/GABA cycle: function, regional differences in glutamate and GABA production and effects of interference with GABA metabolism. Neurochem Res. 2014; 40(2): 402– 9. 25380696 sourceNot checked — no full text of the source
• cites [22] Tapiero H, Mathé G, Couvreur P, Tew KD II. Glutamine and glutamate. Biomed Pharmacother. 2002; 56(9): 446– 57. 12481981 sourceNot checked — no full text of the source
• cites [23] Hakvoort TBM, He Y, Kulik W, Vermeulen JLM, Duijst S, Ruijter JM, et al. Pivotal role of glutamine synthetase in ammonia detoxification. Hepatology. 2017; 65(1): 281– 93. 27641632 sourceCould not verify

  The retrieved passages describe glutamate being converted to glutamine and glutamine catabolism in ammonia detoxification (section and page not provided). Searches for reconversion to glutamate and for neurotransmitter or energy-substrate use found no passage in our copy addressing those uses. (LLM, conf=0.68)

  Experimental — accuracy not yet measured
• cites [24] Rose CF, Verkhratsky A, Parpura V. Astrocyte glutamine synthetase: pivotal in health and disease. Biochem Soc Trans. 2013; 41(6): 1518– 24. 24256247 sourceNot checked — no full text of the source
• cites [25] Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001; 65(1): 1– 105. 11369436 sourceNot checked — no full text of the source
• cites [26] Murphy‐Royal C, Dupuis JP, Varela JA, Panatier A, Pinson B, Baufreton J, et al. Surface diffusion of astrocytic glutamate transporters shapes synaptic transmission. Nat Neurosci. 2015; 18(2): 219– 26. 25581361 sourceNot checked — no full text of the source
• cites [27] Son H, Kim S, Hyuk JD, Baek JH, Lee DH, Roh GS, et al. Insufficient glutamine synthetase activity during synaptogenesis causes spatial memory impairment in adult mice. Sci Rep. 2019; 9(1): 1– 9. 30670758 PMC6342969 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Astrocytes, microglia, and endothelial cells establish tightly articulated physical and molecular interactions in a functionally integrated structure known as the gliovascular unit (GVU), through which many properties of the brain are maintained.

“Astrocytes, microglia, and endothelial cells establish tightly articulated physical and molecular interactions [1, 2, 3, 4] in a functionally integrated structure known as the gliovascular unit (GVU) [5] through which many of the properties of the brain are maintained [3, 4].”

• cites [1] Iadecola C, Nedergaard M. Glial regulation of the cerebral microvasculature. Nat Neurosci. 2007; 10(11): 1369– 76. 17965657 sourceNot checked — no full text of the source
• cites [2] Abbott NJ, Rönnbäck L, Hansson E. Astrocyte‐endothelial interactions at the blood‐brain barrier. Nat Rev Neurosci. 2006 Jan; 7(1): 41– 53. 16371949 sourceNot checked — no full text of the source
• cites [3] Muoio V, Persson PB, Sendeski MM. The neurovascular unit—concept review. Acta Physiol. 2014; 210(4): 790– 8. 24629161 sourceNot checked — no full text of the source
• cites [4] Liedtke W, Edelmann W, Bieri PL, Chiu FC, Cowan NJ, Kucherlapati R, et al. GFAP is necessary for the integrity of CNS white matter architecture and long‐term maintenance of myelination. Neuron. 1996; 17(4): 607– 15. 8893019 sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured
• cites [5] Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci. 2017; 18(7): 419– 34. 28515434 PMC5759779 sourcePartly supported

  Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Astrocytic processes surround most of the vascular surface and regulate blood-brain barrier permeability by modulating tight junction proteins such as claudin-5 and endothelial proteins such as vimentin.

“Astrocytic processes surround most of the vascular surface, regulating the blood–brain barrier (BBB) permeability [6, 7, 8, 9]—by modulating tight junction proteins such as claudin‐5 [10], or endothelial proteins such vimentin, which is associated with the stability of cerebral vasculature [11]—and integrate neuronal activity with blood flow [1, 2, 3, 4, 5, 12, 13, 14, 15, 16, 17, 18, 19, 20].”

• cites [6] Zhao Z, Nelson AR, Betsholtz C, Zlokovic BV. Establishment and dysfunction of the blood‐brain barrier. Cell. 2015; 163(5): 1064– 78. 26590417 PMC4655822 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites [7] Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood‐brain barrier. Nat Med. 2013; 19(12): 1584– 96. 24309662 PMC4080800 sourceSupported
• cites [8] Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 2011; 12(12): 723– 38. 22048062 PMC4036520 sourcePartly supported

  The neurovascular unit section says that glial cells, including astrocytes, act with other cells to control BBB permeability. It does not establish that astrocytic processes surround most of the vascular surface. The blood–brain barrier breakdown section links reduced claudin-5 expression to pericyte deficiency, not astrocytic modulation, and the searched passages do not identify vimentin as an astrocyte-mediated mechanism. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [9] Sweeney MD, Sagare AP, Zlokovic BV. Blood‐brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018; 14(3): 133– 50. 29377008 PMC5829048 sourcePartly supported

  The Introduction (page unavailable) says astrocyte end-feet sheath the endothelial BBB, supporting the claim that astrocytic processes surround the vasculature. It does not establish that they regulate BBB permeability; it describes tight endothelial contacts and limited transcytosis as restricting permeability. The claudin-5 and vimentin mechanisms have separate citations in the citing sentence and are not attributed to this source. (LLM, conf=0.78)

  Experimental — accuracy not yet measured
• cites [10] Lv J, Hu W, Yang Z, Li T, Jiang S, Ma Z, et al. Focusing on claudin‐5: a promising candidate in the regulation of BBB to treat ischemic stroke. Prog Neurobiol. 2018; 161: 79– 96. 29217457 sourceNot checked — no full text of the source
• cites [11] Dave JM, Bayless KJ. Vimentin as an integral regulator of cell adhesion and endothelial sprouting. Microcirculation. 2014; 21: 333– 44. 24387004 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Glutamine synthetase (GS) catalyzes the condensation of ammonium and glutamate into glutamine.

“Complementarily, the cytoplasmic enzyme glutamine synthetase (GS) catalyzes the condensation of ammonium and glutamate into glutamine [24, 27, 29], which in turn can be reconverted into glutamate for use either as a neurotransmitter or energy substrate [21, 22, 23, 24, 25, 26, 27].”

• cites [24] Rose CF, Verkhratsky A, Parpura V. Astrocyte glutamine synthetase: pivotal in health and disease. Biochem Soc Trans. 2013; 41(6): 1518– 24. 24256247 sourceNot checked — no full text of the source
• cites [27] Son H, Kim S, Hyuk JD, Baek JH, Lee DH, Roh GS, et al. Insufficient glutamine synthetase activity during synaptogenesis causes spatial memory impairment in adult mice. Sci Rep. 2019; 9(1): 1– 9. 30670758 PMC6342969 sourceSupported
• cites [29] Albrecht J, Sidoryk‐Wȩgrzynowicz M, Zielińska M, Aschner M. Roles of glutamine in neurotransmission. Neuron Glia Biol. 2010; 6(4): 263– 76. 22018046 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Previous studies of our group have identified molecular differences between SAD and FAD in addition to divergences in clinical manifestations.

“Previous studies of our group have identified molecular differences between SAD and FAD [55, 56, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79] in addition to divergences in the clinical manifestations [55, 56].”

• cites [55] Mendez MF. Early‐onset Alzheimer disease and its variants. Contin Lifelong Learn Neurol. 2019; 25(1): 34– 51. PMC6538053 30707186 sourceSupported
• cites [56] Sepulveda‐Falla D, Glatzel M, Lopera F. Phenotypic profile of early‐onset familial Alzheimer's disease caused by presenilin‐1 E280A mutation. J Alzheimers Dis. 2012; 32(1): 1– 12. 22766738 sourceNot checked — no full text of the source
• cites [70] Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med. 2011; 17(9): 1060– 5. 21900936 sourceNot checked — no full text of the source
• cites [71] Heneka MT, Sastre M, Dumitrescu‐Ozimek L, Dewachter I, Walter J, Klockgether T, et al. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation. 2005; 2: 1– 12. 16212664 PMC1274341 sourcePartly supported

  The Background (page unavailable) links familial Alzheimer’s disease to APP mutations, and the Conclusion (page unavailable) reports increased BACE1 expression and activity in mice carrying a mutant APP gene. The paper does not compare sporadic and familial Alzheimer’s disease or establish molecular differences between them; the clinical-manifestations clause is attributed to other citations. (LLM, conf=0.78)

  Experimental — accuracy not yet measured
• cites [72] Villamil‐Ortiz JG, Barrera‐Ocampo A, Arias‐Londoño JD, Villegas A, Lopera F, Cardona‐Gómez GP. Differential pattern of phospholipid profile in the temporal cortex from E280A‐familiar and sporadic Alzheimer's disease brains. J Alzheimers Dis. 2018; 61(1): 209– 19. 29125487 sourceNot checked — no full text of the source
• cites [73] Villar‐Vesga J, Henao‐Restrepo J, Voshart DC, Aguillón D, Villegas A, Castaño D, et al. Differential profile of systemic extracellular vesicles from sporadic and familiar Alzheimer's disease leads to neuroglial and endothelial cell degeneration. Front Aging Neurosci. 2020; 12: 587989. 33281599 PMC7705379 sourceSupported
• cites [74] Sepulveda‐Falla D, Barrera‐Ocampo A, Hagel C, Korwitz A, Vinueza‐Veloz MF, Zhou K, et al. Familial Alzheimer's disease‐associated presenilin‐1 alters cerebellar activity and calcium homeostasis. J Clin Invest. 2014; 124(4): 1552– 67. 24569455 PMC3973081 sourceNot checked — no full text of the source
• cites [75] Sepulveda‐Falla D, Matschke J, Bernreuther C, Hagel C, Puig B, Villegas A, et al. Deposition of hyperphosphorylated tau in cerebellum of PS1 E280A Alzheimer's disease. Brain Pathol. 2011; 21(4): 452– 63. 21159009 PMC8094246 sourceSupported
• cites [76] Szaruga M, Veugelen S, Benurwar M, Lismont S, Sepulveda‐Falla D, Lleo A, et al. Qualitative changes in human γ‐secretase underlie familial Alzheimer's disease. J Exp Med. 2015; 212(12): 2003– 13. 26481686 PMC4647268 sourceSupported
• cites [77] Dinkel F, Trujillo‐Rodriguez D, Villegas A, Streffer J, Mercken M, Lopera F, et al. Decreased deposition of beta‐amyloid 1‐38 and increased deposition of beta‐amyloid 1‐42 in brain tissue of Presenilin‐1 E280A familial Alzheimer's disease patients. Front Aging Neurosci. 2020; 12: 1– 13. 32848702 PMC7399638 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Reactive morphological changes are driven by an increase of intermediate filament proteins such as GFAP and vimentin.

“Finely tuned morphological changes are driven by an increase of intermediate filament proteins, such as GFAP and vimentin [15, 38, 41, 42, 43], which not only provide mechanical sustenance for the maintenance of astrocyte shape, but also support the functional profile of reactive astrocytes through transcriptional modulation of target genes involved in astroglial and microglial responsiveness [44,”

• cites [15] Verkhratsky A, Nedergaard M. Physiology of astroglia. Physiol Rev. 2018; 98(1): 239– 389. 29351512 PMC6050349 sourcePartly supported

  In “Major Findings from Transcriptional Studies” (page not available), the paper says GFAP and vimentin genes are highly upregulated in reactive astrocytes, reflecting morphological changes. Its GFAP discussion also says deleting these proteins impairs reactivity. These passages support their involvement, but do not establish that increased filament proteins drive the morphological changes. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [38] Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010; 119(1): 7– 35. 20012068 PMC2799634 sourcePartly supported

  The ‘Descriptive features of reactive astrogliosis and glial scars’ section reports GFAP upregulation alongside changes in astrocyte shape, including hypertrophy. The ‘Molecular markers and proteomic characterization’ section identifies GFAP and vimentin as intermediate filament proteins with cyto-architectural functions. Our copy does not establish that vimentin increases during reactive astrogliosis or that increased filament expression drives the morphological changes; the ‘Molecular triggers and regulators’ section instead describes signaling mechanisms controlling those changes. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [41] Simpson JE, Ince PG, Lace G, Forster G, Shaw PJ, Matthews F, et al. Astrocyte phenotype in relation to Alzheimer‐type pathology in the ageing brain. Neurobiol Aging. 2010; 31(4): 578– 90. 18586353 sourceNot checked — no full text of the source
• cites [42] Dossi E, Vasile F, Rouach N. Human astrocytes in the diseased brain. Brain Res Bull. 2018; 136: 139– 56. 28212850 PMC5766741 sourcePartly supported

  The 'Astrogliosis as a hallmark of brain diseases' section reports increased GFAP expression alongside astrocyte hypertrophy. The 'Brain tumours > Structural and morphological changes of astrocytes' section reports GFAP and vimentin co-expression in astrocytomas, but does not establish increased vimentin in reactive astrocytes or that either protein drives their morphological changes. Page numbers are unavailable in our copy. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [43] Verkhratsky A, Ho MS, Vardjan N, Zorec R, Parpura V. General pathophysiology of astroglia. Adv Exp Med Biol. 2019; 1175: 149– 79. 31583588 PMC7188602 sourceSupported

May combine two claims.

Full neuropathological characterization of the APOEch case showed severe extended Aβ pathology similar to other affected E280A carriers, while presenting atypical distribution of p-tau pathology.

“Full neuropathological characterization of this case showed severe extended Aβ pathology, similar to that observed in other affected E280A carriers, while presenting atypical distribution of p‐tau pathology.”

• cites [65] Sepulveda‐Falla D, Sanchez JS, Almeida MC, Boassa D, Acosta‐Uribe J, Vila‐Castelar C, et al. Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia. Acta Neuropathol. 2022; 1: 1– 13. PMC9381462 35838824 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Reactive astroglia increases trophic support, glutamate uptake, isolates lesioned areas favoring regeneration, activates immune pathways, and promotes BBB repair.

“Although reactive astroglia increases trophic support and glutamate uptake, isolates lesioned areas favoring regeneration, activates immune pathways, and promotes BBB repair [38, 43, 45, 46, 47], astrocytes can become dysfunctional and acquire cytotoxic potential under prolonged stress [38, 43].”

• cites [38] Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010; 119(1): 7– 35. 20012068 PMC2799634 sourcePartly supported

  The ‘Functions of reactive astrogliosis and glial scar formation’ section supports glutamate uptake and blood–brain barrier repair, while the inflammation section describes scars that contain lesions and context-dependent immune regulation. It does not establish increased trophic support by reactive astroglia, and its discussion of glial scars says they inhibit axon regeneration rather than favor it. Immune effects are described as both pro- and anti-inflammatory, not simply as activation. (LLM, conf=0.90)

  Experimental — accuracy not yet measured
• cites [43] Verkhratsky A, Ho MS, Vardjan N, Zorec R, Parpura V. General pathophysiology of astroglia. Adv Exp Med Biol. 2019; 1175: 149– 79. 31583588 PMC7188602 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites [45] Hol EM, Pekny M. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol. 2015; 32: 121– 30. 25726916 sourceNot checked — no full text of the source
• cites [46] Lechuga‐Sancho AM, Arroba AI, Frago LM, García‐Cáceres C, Delgado‐Rubín De Célix A, Argente J, et al. Reduction in the number of astrocytes and their projections is associated with increased synaptic protein density in the hypothalamus of poorly controlled diabetic rats. Endocrinology. 2006; 147(11): 5314– 24. 16873533 sourceNot checked — no full text of the source
• cites [47] Verkhratsky A. Astroglial calcium signaling in aging and Alzheimer's disease. Cold Spring Harb Perspect Biol. 2019; 11(7): a035188. 31110130 PMC6601464 sourceNot checked yet

  Not checked in the free run.

Probably not a substantial claim: may not pass S3 (load-bearing).

Through the reactive response, astrocytes aim to restore regional homeostasis by gradually modifying their transcriptional profile and adapting their cell morphology and activity.

“Through the reactive response, astrocytes aim to restore regional homeostasis gradually modifying their transcriptional profile and adapting their cell morphology and activity [15, 38].”

• cites [15] Verkhratsky A, Nedergaard M. Physiology of astroglia. Physiol Rev. 2018; 98(1): 239– 389. 29351512 PMC6050349 sourcePartly supported

  The ‘Major Findings from Transcriptional Studies’ section reports altered transcriptional profiles and morphological changes in reactive astrocytes. The ‘Definition and Overview of Function’ section describes astrocytes’ homeostatic and defensive roles. Our copy does not establish that these reactive changes occur gradually or specifically restore regional homeostasis through adapted activity; no page numbers are available for these passages. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites [38] Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010; 119(1): 7– 35. 20012068 PMC2799634 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Vascular risk factors and the allele APOE4 are the main factors of susceptibility identified to date for AD.

“In particular, vascular risk factors and the allele APOE4 are the main factors of susceptibility identified to date [5, 58].”

• cites [5] Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci. 2017; 18(7): 419– 34. 28515434 PMC5759779 sourcePartly supported

  In “Aβ-independent vascular changes in animal models” (page unavailable), the paper calls APOE4 the major genetic risk factor for AD and identifies hypertension as an AD risk factor. The broader “Alzheimer’s vascular dysfunction” section (page unavailable) also names vascular factors, but it does not establish that vascular risk factors and APOE4 together are the main susceptibility factors identified to date; it lists environmental and lifestyle factors as well. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites [58] Breteler MMB. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging. 2000; 21(2): 153– 60. 10867200 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Unlike FAD, SAD is a more complex disorder in terms of associated triggers, with environmental and genetic elements likely driving the pathology.

“Unlike FAD, SAD is a more complex disorder in terms of the associated triggers. The confluence of environmental and genetic elements is likely to drive the pathology [57].”

• cites [57] Rabinovici BGD. Late‐onset Alzheimer disease. Continuum. 2019; 25: 14– 33. 30707185 PMC6548536 sourcePartly supported

  The Genetic Risk Factors section (p. 3) describes late-onset AD as a complex genetic disorder, and Environmental Risk Factors (p. 3) identifies environmental factors associated with dementia risk. The paper does not establish that these factors jointly drive AD pathology; it says links between many environmental factors and the specific pathobiology of AD are less established. Its comparison with familial early-onset AD (Key Points, p. 4) does not explicitly characterize sporadic disease as more complex. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Approximately 0.6% of AD cases present a hereditary form (FAD) caused by mutations in APP, PSEN1, or PSEN2 that lead to aberrant Aβ overproduction and aggregation.

“However, approximately 0.6% of cases present a hereditary form (familial AD or FAD) caused by mutations in APP, PSEN1, or PSEN2 that lead to aberrant Aβ overproduction and aggregation [55, 56].”

• cites [55] Mendez MF. Early‐onset Alzheimer disease and its variants. Contin Lifelong Learn Neurol. 2019; 25(1): 34– 51. PMC6538053 30707186 sourcePartly supported

  The Genetics section states that about 0.6% of all patients with AD have familial AD associated with mutations in APP, PSEN1, or PSEN2. It says these mutations lead to aberrant cleavage or aggregation of amyloid precursor protein, but does not state that they cause Aβ overproduction and aggregation. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [56] Sepulveda‐Falla D, Glatzel M, Lopera F. Phenotypic profile of early‐onset familial Alzheimer's disease caused by presenilin‐1 E280A mutation. J Alzheimers Dis. 2012; 32(1): 1– 12. 22766738 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

APOE3 has been considered neutral with regard to AD risk.

“In contrast to APOE4, which has been related to higher risk and younger age of AD onset, APOE3 has been considered neutral with regard to AD risk [63].”

• cites [63] Yamazaki Y, Shinohara M, Yamazaki A, Ren Y, Asmann YW, Kanekiyo T, et al. ApoE (Apolipoprotein E) in brain pericytes regulates endothelial function in an isoform‐dependent manner by modulating basement membrane components. Arterioscler Thromb Vasc Biol. 2020; 40(1): 128– 44. 31665905 PMC7007705 sourceSupported

May combine two claims.

APOE was among the differentially expressed genes in astrocytes and microglia in APOEch, with an expression gradient from high in frontal cortex to low in occipital cortex, which exhibited a distinctive chronic inflammatory microglial profile and severe p-tau pathology.

“APOE was among the differentially expressed genes in astrocytes and microglia in APOEch, with an expression gradient from high in frontal cortex to low in occipital cortex, which in turn exhibited a distinctive chronic inflammatory microglial profile and severe p‐tau pathology [65].”

• cites [65] Sepulveda‐Falla D, Sanchez JS, Almeida MC, Boassa D, Acosta‐Uribe J, Vila‐Castelar C, et al. Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia. Acta Neuropathol. 2022; 1: 1– 13. PMC9381462 35838824 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

AD is characterized by the aggregation of Aβ and p-tau.

“AD is characterized by the aggregation of Aβ and p‐tau [53].”

• cites [53] Jack CR, Hampel HJ, Universities S, Cu M, Petersen RC. A new classification system for AD, independent of cognition A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016; 87(5): 1– 10. https://n.neurology.org/content/87/5/539 sourcePartly supported

  The AD BIOMARKERS section describes fibrillary Aβ deposition and neurofibrillary tangles as AD-related pathologies. It identifies elevated CSF p-tau as a biomarker of tau pathology, but does not say that p-tau itself aggregates; the claim is more specific on that point than the paper. (LLM, conf=0.78)

  Experimental — accuracy not yet measured

May combine two claims.

Frontal cortex of APOEch showed one of the highest accumulations of Aβ compared to other brain regions but significantly lower levels of p-tau.

“Frontal cortex of APOEch showed one of the highest accumulations of Aβ compared to other brain regions but significantly lower levels of p‐tau [65], making it an interesting region to investigate at the astroglial and gliovascular levels.”

• cites [65] Sepulveda‐Falla D, Sanchez JS, Almeida MC, Boassa D, Acosta‐Uribe J, Vila‐Castelar C, et al. Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia. Acta Neuropathol. 2022; 1: 1– 13. PMC9381462 35838824 sourceSupported

May combine two claims.

APOEch showed upregulation of homeostatic genes in astrocytes of the frontal cortex and a signature for acute immune response.

“In fact, APOEch showed upregulation of homeostatic genes in the astrocytes of the frontal cortex and a signature for acute immune response.”

• cites [65] Sepulveda‐Falla D, Sanchez JS, Almeida MC, Boassa D, Acosta‐Uribe J, Vila‐Castelar C, et al. Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia. Acta Neuropathol. 2022; 1: 1– 13. PMC9381462 35838824 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Astrocytes can become dysfunctional and acquire cytotoxic potential under prolonged stress.

“astrocytes can become dysfunctional and acquire cytotoxic potential under prolonged stress [38, 43].”

• cites [38] Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010; 119(1): 7– 35. 20012068 PMC2799634 sourceSupported
• cites [43] Verkhratsky A, Ho MS, Vardjan N, Zorec R, Parpura V. General pathophysiology of astroglia. Adv Exp Med Biol. 2019; 1175: 149– 79. 31583588 PMC7188602 sourceSupported

Classified as probably not a substantial claim. May combine two claims.

More integrative hypotheses have suggested that inflammation, excitatory-inhibitory imbalance, or vascular impairment is involved in the series of initial reactions that eventually become chronic and result in irreversible brain dyshomeostasis, neurodegeneration, and AD.

“Therefore, more integrative hypotheses have suggested that inflammation, excitatory‐inhibitory imbalance, or vascular impairment is involved in the series of initial reactions that eventually become chronic and result in irreversible brain dyshomeostasis, neurodegeneration, and AD [42, 66, 69].”

• cites [42] Dossi E, Vasile F, Rouach N. Human astrocytes in the diseased brain. Brain Res Bull. 2018; 136: 139– 56. 28212850 PMC5766741 sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured
• cites [66] Littau JL, Velilla L, Hase Y, Villalba‐Moreno ND, Hagel C, Drexler D, et al. Evidence of beta amyloid independent small vessel disease in familial Alzheimer's disease. Brain Pathol. 2022; e13097. 35695802 PMC9616091 sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured
• cites [69] Ricciarelli R, Fedele E. The amyloid cascade hypothesis in Alzheimer's disease: it's time to change our mind. Curr Neuropharmacol. 2017; 15(6): 926– 35. 28093977 PMC5652035 sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Astrocyte reactivity has frequently been associated with neuroinflammation, unfavorable glial scar formation, glutamate dyshomeostasis, altered coverage of synapses and blood vessels, and BBB breakout.

“Hence, astrocyte reactivity has frequently been associated with neuroinflammation, unfavorable glial scar formation [7, 8, 9, 37, 38, 43, 48, 49], glutamate dyshomeostasis [43, 50, 51], altered coverage of synapses and blood vessels, and BBB breakout [38, 42, 43, 45, 46, 47].”

• cites [7] Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood‐brain barrier. Nat Med. 2013; 19(12): 1584– 96. 24309662 PMC4080800 sourcePartly supported

  The sections on epilepsy and ALS link astrocytic inflammatory activity with increased BBB permeability and describe reduced astrocyte glutamate transport and swollen perivascular end-feet. They do not establish the full claimed association of astrocyte reactivity with unfavorable glial scars or altered synaptic coverage, and the BBB findings are presented in specific disease contexts rather than as a general consequence of reactivity. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [8] Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 2011; 12(12): 723– 38. 22048062 PMC4036520 sourcePartly supported

  In “Blood–brain barrier breakdown” (page unavailable), the review describes BBB disruption and says that associated ischaemia–hypoxia can cause astrocytes to swell. In “Hypoperfusion and hypoxia” (page unavailable), it reports suppressed astrocyte glutamate reuptake. These passages support related BBB and glutamate changes, but do not establish the claimed frequent association of astrocyte reactivity with BBB breakdown, altered synaptic and vascular coverage, or unfavorable glial scarring. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [9] Sweeney MD, Sagare AP, Zlokovic BV. Blood‐brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018; 14(3): 133– 50. 29377008 PMC5829048 sourcePartly supported

  The Introduction describes astrocyte end-feet covering brain vessels and associates BBB breakdown with inflammatory responses. The ‘BBB breakdown and neurodegeneration’ section says neurotoxic material and reduced blood flow can activate astrocytes, leading to inflammation. These passages support an association among BBB disruption, astrocyte activation and inflammation, but do not establish altered astrocyte coverage of synapses or vessels as a feature of astrocyte reactivity. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [37] Jha MK, Jo M, Kim JH, Suk K. Microglia‐astrocyte crosstalk: an intimate molecular conversation. Neuroscientist. 2019; 25: 227– 40. 29931997 sourceNot checked — no full text of the source
• cites [38] Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010; 119(1): 7– 35. 20012068 PMC2799634 sourcePartly supported

  The sections on mechanisms of reactive astrogliosis and CNS inflammation associate reactive astrocytes, under specific circumstances, with inflammation, inhibition of axon regeneration by glial scars, glutamate-related harm, and compromised blood–brain barrier function. The copy does not clearly link reactivity to altered coverage of both synapses and blood vessels. It also emphasizes that reactive astrogliosis and scars can be protective, so the uniformly unfavorable framing overstates the review. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [43] Verkhratsky A, Ho MS, Vardjan N, Zorec R, Parpura V. General pathophysiology of astroglia. Adv Exp Med Biol. 2019; 1175: 149– 79. 31583588 PMC7188602 sourcePartly supported

  The Reactive Astrogliosis section (page unavailable) links reactivity to scar formation and says reactive astrocytes can become maladaptive under prolonged stress or severe damage. But it describes scars as generally protective and reactivity as helping reconstruct a compromised blood–brain barrier; the Neurotrauma section likewise describes glutamate removal as a protective function. The copy does not establish the claimed association of reactivity with glutamate dyshomeostasis, altered synaptic and vascular coverage, or BBB breakout. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [48] Liu CY, Yang Y, Ju WN, Wang X, Zhang HL. Emerging roles of astrocytes in neuro‐vascular unit and the tripartite synapse with emphasis on reactive gliosis in the context of Alzheimer's disease. Front Cell Neurosci. 2018; 12: 1– 12. 30042661 PMC6048287 sourcePartly supported

  The Astrogliosis section associates reactive astrocytes with inflammation and says severe astrogliosis can involve scar formation; it also discusses inflammatory mediators from activated astrocytes that may contribute to BBB deterioration. But the paper places reduced coverage of vessels and synapses and disrupted glutamate homeostasis under Astro-degeneration, not reactivity. It also describes normal astrogliosis as supporting glutamate uptake and BBB repair, so it does not support presenting the entire list as unfavorable consequences of reactivity. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [49] Matias I, Morgado J, Gomes FCA. Astrocyte heterogeneity: impact to brain aging and disease. Front Aging Neurosci. 2019; 11: 1– 18. 30941031 PMC6433753 sourcePartly supported

  The section on reactive astrocyte phenotypes (page unavailable) links reactivity to inflammatory responses and scar formation. The neurodegenerative-diseases section suggests that astrocyte atrophy may diminish synaptic coverage and impair the neurovascular unit, but does not establish those effects generally. The copy describes normal astrocytic control of glutamate and says BBB disruption affects the extent of reactivity; it does not establish glutamate dyshomeostasis or BBB breakdown as consequences of reactivity. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [50] Osipova ED, Semyachkina‐Glushkovskaya OV, Morgun AV, Pisareva NV, Malinovskaya NA, Boitsova EB, et al. Gliotransmitters and cytokines in the control of blood‐brain barrier permeability. Rev Neurosci. 2018; 29(5): 567– 91. 29306934 sourceNot checked — no full text of the source
• cites [51] Vazana U, Veksler R, Pell GS, Prager O, Fassler M, Chassidim Y, et al. Glutamate‐mediated blood–brain barrier opening: implications for neuroprotection and drug delivery. J Neurosci. 2016; 36(29): 7727– 39. 27445149 PMC4951577 sourcePartly supported

  The Discussion (page not available in our copy) says increased BBB permeability can induce an astrocytic transformation associated with neuroinflammation and impaired control of the extracellular milieu. That supports an association involving astrocyte reactivity and BBB dysfunction, but the paper does not establish the cited sentence’s additional claims about glial scarring or altered coverage of synapses and blood vessels, nor does it directly link astrocyte reactivity to glutamate dyshomeostasis. (LLM, conf=0.83)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

The E280A mutation generally produces a more aggressive course of pathology than SAD.

“which generally produces a more aggressive course of pathology than SAD [55, 56].”

• cites [55] Mendez MF. Early‐onset Alzheimer disease and its variants. Contin Lifelong Learn Neurol. 2019; 25(1): 34– 51. PMC6538053 30707186 sourcePartly supported

  The Clinical Features section says early-onset AD can have a more aggressive clinical course than late-onset AD, and the Neuropathology section describes differences in pathological burden. Neither passage establishes that the E280A mutation specifically produces a more aggressive course of pathology than sporadic AD (SAD). (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites [56] Sepulveda‐Falla D, Glatzel M, Lopera F. Phenotypic profile of early‐onset familial Alzheimer's disease caused by presenilin‐1 E280A mutation. J Alzheimers Dis. 2012; 32(1): 1– 12. 22766738 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Together with microglia, astrocytes constitute the principal defensive system of the CNS and respond to damage-related stimuli including Aβ and glutamate overload in a process known as astrocyte reactivity.

“Together with microglia, astrocytes constitute the principal defensive system of the CNS [37], responding to numerous damage‐related stimuli [6, 7, 8, 9] including amyloid β peptides (Aβ) and glutamate overload, in a process known as astrocyte reactivity [15, 37, 38, 39, 40].”

• cites [37] Jha MK, Jo M, Kim JH, Suk K. Microglia‐astrocyte crosstalk: an intimate molecular conversation. Neuroscientist. 2019; 25: 227– 40. 29931997 sourceNot checked — no full text of the source
• cites [6] Zhao Z, Nelson AR, Betsholtz C, Zlokovic BV. Establishment and dysfunction of the blood‐brain barrier. Cell. 2015; 163(5): 1064– 78. 26590417 PMC4655822 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites [7] Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood‐brain barrier. Nat Med. 2013; 19(12): 1584– 96. 24309662 PMC4080800 sourcePartly supported

  The section ‘The role of astrocytes in BBB regulation’ says astrocytes control immune reactions, and ‘BBB compromise in chronic neurodegeneration: ALS’ reports that microglia and astrocytes become activated after tissue injury. These passages support a defensive role and an activation response, but do not call the two cell types the CNS’s principal defensive system or identify the response as ‘astrocyte reactivity.’ The cited paper also does not substantiate Aβ or glutamate overload as triggers in this account. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [8] Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 2011; 12(12): 723– 38. 22048062 PMC4036520 sourcePartly supported

  The neurovascular-unit section describes glia as helping maintain the brain’s chemical environment, and the Alzheimer’s disease section reports that astrocytes and microglia help clear amyloid-β. These passages support a protective role, but they do not call astrocytes and microglia the CNS’s principal defensive system or describe responses to amyloid-β and glutamate overload as ‘astrocyte reactivity.’ The transport-across-the-blood–brain-barrier section discusses glutamate removal at the BBB, not astrocyte reactivity. (LLM, conf=0.81)

  Experimental — accuracy not yet measured
• cites [9] Sweeney MD, Sagare AP, Zlokovic BV. Blood‐brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018; 14(3): 133– 50. 29377008 PMC5829048 sourcePartly supported

  The ‘BBB breakdown and neurodegeneration’ section says that accumulated neurotoxic material and reduced blood flow can activate both microglia and astrocytes, leading to inflammation. It does not describe them as the CNS’s principal defensive system or identify Aβ and glutamate overload as triggers of astrocyte reactivity; the ‘BBB molecular architecture’ section discusses Aβ and glutamate clearance at the BBB instead. No page numbers are available in our copy. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [15] Verkhratsky A, Nedergaard M. Physiology of astroglia. Physiol Rev. 2018; 98(1): 239– 389. 29351512 PMC6050349 sourceSupported
• cites [38] Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010; 119(1): 7– 35. 20012068 PMC2799634 sourceSupported
• cites [39] Hoogland ICM, Houbolt C, Van Westerloo DJ, Van Gool WA, Van De Beek D. Systemic inflammation and microglial activation: systematic review of animal experiments. J Neuroinflammation. 2012; 12: 114. PMC4470063 26048578 sourcePartly supported

  The Introduction (page unavailable) describes microglia as major CNS immune cells that survey for damage. The Discussion (page unavailable) says astrocytes release ATP in response to neuronal injury, but it does not describe astrocytes and microglia together as the principal CNS defensive system or identify Aβ, glutamate overload, and astrocyte reactivity as claimed. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites [40] Murugan M, Ling E‐A, Kaur C. Glutamate receptors in microglia. CNS Neurol Disord Drug Targets. 2013; 12(6): 773– 84. 24047523 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The astroglial reactive response is a context-specific reaction influenced by brain region, pathology, disease stage, genetics, age, and comorbidities, and is characteristic of multiple brain pathologies including Alzheimer's disease.

“The astroglial reactive response is far from a uniform process. Rather, it is a context‐specific reaction influenced by brain region, pathology, disease stage, genetics, age, and comorbidities [15, 43, 45, 52], and it is characteristic of multiple brain pathologies, including Alzheimer's disease (AD).”

• cites [15] Verkhratsky A, Nedergaard M. Physiology of astroglia. Physiol Rev. 2018; 98(1): 239– 389. 29351512 PMC6050349 sourcePartly supported

  The section “Major Findings From Transcriptional Studies” (page unavailable) says reactive astrogliosis is common in brain injury and disease and that responses in two injury models were not uniform but depended on pathology. The GFAP discussion also reports that genetic deletion impairs reactivity. The passages found do not establish that the reactive response varies with brain region, disease stage, age, or comorbidities, or that it is characteristic of Alzheimer’s disease specifically. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [43] Verkhratsky A, Ho MS, Vardjan N, Zorec R, Parpura V. General pathophysiology of astroglia. Adv Exp Med Biol. 2019; 1175: 149– 79. 31583588 PMC7188602 sourcePartly supported

  In “Principles of Astrogliopathology,” the paper says astroglial changes vary by disease and stage and are affected by age and comorbidity; “Reactive Astrogliosis” describes varied, disease-specific phenotypes. The paper also reports reactive astrogliosis in many neurological disorders and discusses it in an Alzheimer’s disease model. The passages do not establish genetics as an influence on the reactive response, and the stroke section’s variation with distance from an ischemic core does not establish variation by brain region. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [45] Hol EM, Pekny M. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol. 2015; 32: 121– 30. 25726916 sourceNot checked — no full text of the source
• cites [52] Clarke LE, Liddelow SA, Chakraborty C, Münch AE, Heiman M, Barres BA. Normal aging induces A1‐like astrocyte reactivity. Proc Natl Acad Sci U S A. 2018; 115(8): E1896– 905. 29437957 PMC5828643 sourcePartly supported

  The Abstract reports that astrocyte reactivity varies by brain region and age, and the Discussion links A1 astrocytes to several neurodegenerative diseases, including Alzheimer’s disease (page numbers unavailable). The paper does not establish disease stage, genetics, or comorbidities as influences on the reactive response. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Astrocytes are the major producers of cerebral ApoE, which plays a relevant role in Aβ clearance.

“Notably, astrocytes are the major producers of cerebral ApoE [64], which has been reported to play a relevant role in Aβ clearance [63].”

• cites [64] Riddell DR, Zhou H, Atchison K, Warwick HK, Atkinson PJ, Jefferson J, et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci. 2008; 28(45): 11445– 53. 18987181 PMC6671315 sourceSupported
• cites [63] Yamazaki Y, Shinohara M, Yamazaki A, Ren Y, Asmann YW, Kanekiyo T, et al. ApoE (Apolipoprotein E) in brain pericytes regulates endothelial function in an isoform‐dependent manner by modulating basement membrane components. Arterioscler Thromb Vasc Biol. 2020; 40(1): 128– 44. 31665905 PMC7007705 sourcePartly supported

  The Results (Characterization of primary brain pericytes; page unavailable) report that cultured mouse astrocytes secreted roughly three to four times as much ApoE as pericytes, while endothelial cells secreted less. This supports astrocytes as substantial ApoE producers, but the comparison of cultured cells does not establish that they are the major producers of cerebral ApoE overall. The Aβ-clearance statement is attributed to a different citation, [63], and is not judged here. (LLM, conf=0.81)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

Astroglial reactivity impacts astrocyte-dependent glutamate homeostasis.

“As astroglial reactivity impacts astrocyte‐dependent glutamate homeostasis [36, 94, 95, 96, 97]”

• cites [36] Sullivan SM, Lee A, Björkman ST, Miller SM, Sullivan RKP, Poronnik P, et al. Cytoskeletal anchoring of GLAST determines susceptibility to brain damage: an identified role for GFAP. J Biol Chem. 2007; 282(40): 29414– 23. 17684014 sourceSupported
• cites [94] Ortinski PI, Dong J, Mungenast A, Yue C, Takano H, Watson DJ, et al. Selective induction of astrocytic gliosis generates deficits in neuronal inhibition. Nat Neurosci. 2010; 13(5): 584– 91. 20418874 PMC3225960 sourceSupported
• cites [95] Fluteau A, Ince PG, Minett T, Matthews FE, Brayne C, Garwood CJ, et al. The nuclear retention of transcription factor FOXO3a correlates with a DNA damage response and increased glutamine synthetase expression by astrocytes suggesting a neuroprotective role in the ageing brain. Neurosci Lett. 2015; 609: 11– 7. 26455863 PMC4674771 sourcePartly supported

  The Introduction and Discussion describe astrocytes’ role in glutamate homeostasis and suggest that their response to oxidative stress can alter glutamine synthetase expression. But the Results report no significant correlation between glutamine-synthetase-positive astrocytes and astrogliosis, so this paper does not establish that astroglial reactivity itself impacts glutamate homeostasis. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites [96] Takaki J, Fujimori K, Miura M, Suzuki T, Sekino Y, Sato K. L‐glutamate released from activated microglia downregulates astrocytic L‐glutamate transporter expression in neuroinflammation: the “collusion” hypothesis for increased extracellular L‐glutamate concentration in neuroinflammation. J Neuroinflammation. 2012; 9: 1– 17. 23259598 PMC3575281 sourcePartly supported

  The Background and Discussion describe how inflammation-associated changes in astrocytic glutamate transport impair extracellular glutamate regulation. But the Results attribute the effect in this model to activated microglia and report no observed changes in astrocyte morphology; they do not establish astroglial reactivity itself as the cause. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [97] Jo S, Yarishkin O, Hwang YJ, Chun YE, Park M, Woo DH, et al. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease. Nat Med. 2014; 20(8): 886– 96. 24973918 PMC8385452 sourcePartly supported

  The Results (Reactive astrocytes abnormally release GABA; page unavailable) show that the glutamate-releasing Best1 channel is reduced in the synaptic microdomains of reactive astrocytes in AD-model mice. The Discussion describes its redistribution, but the paper does not establish an effect on glutamate homeostasis, such as altered glutamate uptake or extracellular levels. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

Astrocytes are organized into distinct functional-associated layers throughout the grey matter.

“Considering that astrocytes are organized into distinct functional‐associated layers throughout the GM [98, 99, 100, 101]”

• cites [98] Bayraktar OA, Bartels T, Holmqvist S, Kleshchevnikov V, Martirosyan A, Polioudakis D, et al. Astrocyte layers in the mammalian cerebral cortex revealed by a single‐cell in situ transcriptomic map. Nat Neurosci. 2020; 23(4): 500– 9. 32203496 PMC7116562 sourcePartly supported

  The Results (‘Astrocyte layers diverge from neuronal laminae’) state that astrocytes form multiple layers across the cortical gray matter. The Results (‘Astrocyte layer characteristics vary between cortical areas’) also show that layer markers differ between functional cortical areas. The paper does not establish distinct functions for those layers or extend the finding to gray matter outside the cortex. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [99] Morel L, Chiang MSR, Higashimori H, Shoneye T, Iyer LK, Yelick J, et al. Molecular and functional properties of regional astrocytes in the adult brain. J Neurosci. 2017; 37(36): 8706– 17. 28821665 PMC5588463 sourcePartly supported

  The Introduction describes spatial domains and region-dependent functional differences among astrocytes. But the Discussion says how astrocytes regulate local circuitry in different cortical layers remains essentially unknown; the paper does not establish distinct functional layers throughout grey matter. The indexed passages provide section labels but no page numbers. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [100] Köhler S, Winkler U, Hirrlinger J. Heterogeneity of astrocytes in grey and white matter. Neurochem Res. 2019; 46: 3– 14. 31797158 sourceNot checked — no full text of the source
• cites [101] Morel L, Men Y, Chiang MSR, Tian Y, Jin S, Yelick J, et al. Intracortical astrocyte subpopulations defined by astrocyte reporter mice in the adult brain. Glia. 2019; 67(1): 171– 81. 30430665 sourceNot checked — no full text of the source

May combine two claims.

GFAP astrocytes were almost limited to layer II in CNT, while they were abundant throughout layers I-III in AD.

“Consistent with previous reports [90, 91] and similar to vimentin, GFAP astrocytes were almost limited to layer II in CNT, while they were abundant throughout layers I–III in AD.”

• cites [90] DeFelipe J, Alonso‐Nanclares L, Arellano JI. Microstructure of the neocortex: comparative aspects. J Neurocytol. 2002; 31: 299– 316. 12815249 sourceNot checked — no full text of the source
• cites [91] Hol EM, Capetanaki Y. Type III intermediate filaments desmin, glial fibrillary acidic protein (GFAP), vimentin, and peripherin. Cold Spring Harb Perspect Biol. 2017; 9(12): 1– 18. PMC5710105 29196434 sourcePartly supported

  Section 3.2.2 (page unavailable) reports increased GFAP in Alzheimer’s brain tissue, supporting the general association with AD. It does not report that GFAP-positive astrocytes are largely confined to layer II in controls or abundant across layers I–III in AD. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

GFAP influences astrocyte morphology.

“Considering the differential abundance of GFAP in AD and APOEch, and as GFAP influences astrocyte morphology [45, 91, 92, 93], we analyzed morphometric descriptors related to the scale, complexity, and shape of both the astrocytes themselves and their spatial domains.”

• cites [45] Hol EM, Pekny M. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol. 2015; 32: 121– 30. 25726916 sourceNot checked — no full text of the source
• cites [91] Hol EM, Capetanaki Y. Type III intermediate filaments desmin, glial fibrillary acidic protein (GFAP), vimentin, and peripherin. Cold Spring Harb Perspect Biol. 2017; 9(12): 1– 18. PMC5710105 29196434 sourceSupported
• cites [92] Middeldorp J, Hol EM. GFAP in health and disease. Prog Neurobiol. 2011; 93(3): 421– 43. 21219963 sourceNot checked — no full text of the source
• cites [93] Sepulveda‐Falla D, Arboleda‐Velasquez JF. Distinct autosomal dominant Alzheimer's disease tau pathology distribution and single‐cell transcriptome profiles associated with delayed clinical onset in an APOE3 Christchurch homozygote. Nat Med. 2022 (in review). sourceCould not verify

  The Results (Neuropathological findings; page unavailable) use GFAP as an astrocytic marker and report its staining pattern, but do not say that GFAP influences astrocyte morphology. Searches for GFAP with astrocyte morphology and related structural terms found no passage addressing that relationship. (LLM, conf=0.72)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim. May combine two claims.

AQP4 alteration is associated with glymphatic dysfunction and increased Aβ burden.

“Considering that AQP4 is the gold‐standard marker for astrocyte endfeet, and its alteration has been associated with glymphatic dysfunction [103] and increased Aβ burden [104]”

• cites [103] Rasmussen MK, Mestre H, Nedergaard M. The glymphatic pathway in neurological disorders. Lancet Neurol. 2018; 17(11): 1016– 24. 30353860 PMC6261373 sourceSupported
• cites [104] Zeppenfeld DM, Simon M, Haswell JD, D'Abreo D, Murchison C, Quinn JF, et al. Association of perivascular localization of aquaporin‐4 with cognition and Alzheimer disease in aging brains. JAMA Neurol. 2017; 74(1): 91– 9. 27893874 sourceNot checked — no full text of the source

• AssumptionRests on an assumption: AQP4 is the gold-standard marker for astrocyte endfeet.

May combine two claims.

The percentage of p-tau was higher in FAD than in SAD, and the lowest levels were found in APOEch, which was similar to CNT.

“Similarly, the percentage of p‐tau was higher in FAD than in SAD, as previously reported [77], but the lowest levels were found in APOEch which was similar to CNT (Figure 1C,D).”

• cites [77] Dinkel F, Trujillo‐Rodriguez D, Villegas A, Streffer J, Mercken M, Lopera F, et al. Decreased deposition of beta‐amyloid 1‐38 and increased deposition of beta‐amyloid 1‐42 in brain tissue of Presenilin‐1 E280A familial Alzheimer's disease patients. Front Aging Neurosci. 2020; 12: 1– 13. 32848702 PMC7399638 sourcePartly supported

  The Results section reports significantly higher pTau signal in FAD than SAD, but specifically in the occipital cortex and cerebellum; the Discussion says significance was limited to those regions. The citation follows “as previously reported,” so the APOEch and CNT comparison, which the citing sentence assigns to its own Figure 1, is not attributed to this source. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

Endothelial proteins support the functional properties of the brain microvasculature.

“As endothelial proteins support the functional properties of the brain microvasculature [11, 105]”

• cites [11] Dave JM, Bayless KJ. Vimentin as an integral regulator of cell adhesion and endothelial sprouting. Microcirculation. 2014; 21: 333– 44. 24387004 sourceNot checked — no full text of the source
• cites [105] Greene C, Hanley N, Campbell M. Claudin‐5: gatekeeper of neurological function. Fluids Barriers CNS. 2019; 16: 3. 30691500 PMC6350359 sourceSupported

May combine two claims.

Vimentin astrocytes were almost restricted to layer II in CNT, and their distribution in APOEch was remarkably similar, accumulating 80% of cells at around 500 μm in depth.

“As previously described for healthy brains [91], vimentin astrocytes were almost restricted to layer II in CNT, and their distribution in APOEch was remarkably similar to that, accumulating 80% of cells at around 500 μm in depth (Figure 2A,C).”

• cites [91] Hol EM, Capetanaki Y. Type III intermediate filaments desmin, glial fibrillary acidic protein (GFAP), vimentin, and peripherin. Cold Spring Harb Perspect Biol. 2017; 9(12): 1– 18. PMC5710105 29196434 sourceCould not verify

  The citation is attached to the comparison with healthy brains, not to the citing authors’ CNT and APOEch measurements. Our copy discusses astrocytes and vimentin, but the passages in §3.1.1 and §3.2.3 do not describe vimentin-positive astrocytes as nearly restricted to cortical layer II. Searches for layer II, cortical distribution, and the reported depth yielded no supporting passage; page numbers were not available. (LLM, conf=0.74)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Typical human astrocytes display a radial stellate morphology.

“Typical human astrocytes display a radial stellate morphology [38, 108]”

• cites [38] Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010; 119(1): 7– 35. 20012068 PMC2799634 sourcePartly supported

  The Basic astrocyte morphology and Anatomical organization sections describe protoplasmic astrocytes as having several stem branches with fine processes distributed around the cell, which broadly supports a stellate description. But the paper also distinguishes fibrous astrocytes and notes that human astrocytes are structurally diverse; it does not establish radial stellate morphology as typical of human astrocytes generally. Page numbers were not available in our copy. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [108] Oberheim NA, Wang X, Goldman S, Nedergaard M. Astrocytic complexity distinguishes the human brain. Trends Neurosci. 2006; 29(10): 547– 53. 16938356 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Hyperactivated astrocytes and microglia support excitotoxicity through the exacerbated release of glutamate in response to Aβ, and GABA‐producing astrocytes are commonly found in AD.

“hyperactivated astrocytes and microglia, support excitotoxicity through the exacerbated release of glutamate in response to Aβ [37, 38, 40, 43, 50, 51, 117, 118], and even GABA‐producing astrocytes are commonly found in AD [42, 97, 119].”

• cites [37] Jha MK, Jo M, Kim JH, Suk K. Microglia‐astrocyte crosstalk: an intimate molecular conversation. Neuroscientist. 2019; 25: 227– 40. 29931997 sourceNot checked — no full text of the source
• cites [38] Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010; 119(1): 7– 35. 20012068 PMC2799634 sourcePartly supported

  The Alzheimer’s disease section reports reactive astrocytes near amyloid plaques and declining astrocyte glutamate transporters that may increase vulnerability to excitotoxicity. The mechanisms section says reactive astrocytes can release potentially excitotoxic glutamate. Neither passage establishes exacerbated glutamate release by astrocytes and microglia in response to Aβ, or that GABA-producing astrocytes are common in AD. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [40] Murugan M, Ling E‐A, Kaur C. Glutamate receptors in microglia. CNS Neurol Disord Drug Targets. 2013; 12(6): 773– 84. 24047523 sourceNot checked — no full text of the source
• cites [43] Verkhratsky A, Ho MS, Vardjan N, Zorec R, Parpura V. General pathophysiology of astroglia. Adv Exp Med Biol. 2019; 1175: 149– 79. 31583588 PMC7188602 sourcePartly supported

  The Hyperammonemia and Hepatic Encephalopathy section says astrocytes release glutamate that exacerbates excitotoxic damage, but attributes this to ammonium exposure, not Aβ. The Reactive Astrogliosis section says Aβ triggers astroglial reactivity; it does not connect that response to glutamate release. The retrieved passages do not establish microglial glutamate release or that GABA-producing astrocytes are common in Alzheimer’s disease (pages unavailable). (LLM, conf=0.79)

  Experimental — accuracy not yet measured
• cites [50] Osipova ED, Semyachkina‐Glushkovskaya OV, Morgun AV, Pisareva NV, Malinovskaya NA, Boitsova EB, et al. Gliotransmitters and cytokines in the control of blood‐brain barrier permeability. Rev Neurosci. 2018; 29(5): 567– 91. 29306934 sourceNot checked — no full text of the source
• cites [51] Vazana U, Veksler R, Pell GS, Prager O, Fassler M, Chassidim Y, et al. Glutamate‐mediated blood–brain barrier opening: implications for neuroprotection and drug delivery. J Neurosci. 2016; 36(29): 7727– 39. 27445149 PMC4951577 sourceCould not verify

  The Introduction and 'Excessive glutamate release enhances vascular permeability' section discuss glutamate released with neuronal activation and its effects on the blood–brain barrier. Our copy does not address Aβ-induced glutamate release by astrocytes or microglia, or the prevalence of GABA-producing astrocytes in Alzheimer’s disease. Searches for those terms found no supporting passage; page numbers were not supplied. (LLM, conf=0.75)

  Experimental — accuracy not yet measured
• cites [117] Talantova M, Sanz‐Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto SI, et al. Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A. 2013; 110(27): E2518– 27. 23776240 PMC3704025 sourcePartly supported

  The Discussion reports that oligomeric Aβ induces excessive glutamate release from astrocytes, activating extrasynaptic NMDA receptors and contributing to synaptic damage. The FRET-Based Imaging section does not establish glutamate release by microglia; it reports that removing microglia did not change the measured release. The GABA-producing-astrocyte clause has different citations and is not attributed to this source. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [118] Suzumura A. Neuron‐microglia interaction in neuroinflammation. Curr Protein Pept Sci. 2013; 14(1): 16– 20. 23544747 sourceNot checked — no full text of the source
• cites [42] Dossi E, Vasile F, Rouach N. Human astrocytes in the diseased brain. Brain Res Bull. 2018; 136: 139– 56. 28212850 PMC5766741 sourcePartly supported

  The Alzheimer’s disease sections report Aβ-triggered astrocyte activation and GABA accumulation in reactive astrocytes from post-mortem AD patients; increased GABA production is presented as a suggestion. The paper also reports impaired astrocytic glutamate clearance and enhanced glutamatergic gliotransmission in AD mice, but the passages do not establish that astrocytes and microglia release excess glutamate in response to Aβ or that GABA-producing astrocytes are commonly found across AD. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [97] Jo S, Yarishkin O, Hwang YJ, Chun YE, Park M, Woo DH, et al. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease. Nat Med. 2014; 20(8): 886– 96. 24973918 PMC8385452 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Alteration of cell shape is one of the changes associated with astroglial reactivity and modification of vimentin and GFAP.

“alteration of cell shape is one of the changes associated with astroglial reactivity and modification of vimentin and GFAP [15, 28, 42, 43, 91].”

• cites [15] Verkhratsky A, Nedergaard M. Physiology of astroglia. Physiol Rev. 2018; 98(1): 239– 389. 29351512 PMC6050349 sourceSupported
• cites [28] Verkhratsky A, Ho MS, Vardjan N, Zorec R, Parpura V, Verkhratsky A. General pathophysiology of astroglia HHS public access. Adv Exp Med Biol. 2019; 1175: 149– 79. 31583588 PMC7188602 sourceSupported
• cites [42] Dossi E, Vasile F, Rouach N. Human astrocytes in the diseased brain. Brain Res Bull. 2018; 136: 139– 56. 28212850 PMC5766741 sourcePartly supported

  The “Astrogliosis as a hallmark of brain diseases” section associates reactive astrogliosis with cell-body and process hypertrophy and increased GFAP expression. The “Brain tumours > Structural and morphological changes of astrocytes” section discusses vimentin alongside GFAP in astrocytomas, but does not establish that vimentin is modified as part of astroglial reactivity. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [43] Verkhratsky A, Ho MS, Vardjan N, Zorec R, Parpura V. General pathophysiology of astroglia. Adv Exp Med Biol. 2019; 1175: 149– 79. 31583588 PMC7188602 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites [91] Hol EM, Capetanaki Y. Type III intermediate filaments desmin, glial fibrillary acidic protein (GFAP), vimentin, and peripherin. Cold Spring Harb Perspect Biol. 2017; 9(12): 1– 18. PMC5710105 29196434 sourcePartly supported

  Section 3.2.2 (GFAP in Reactive Gliosis; page unavailable) says reactive gliosis involves increased GFAP and vimentin and thicker intermediate-filament bundles in astrocytic processes. It does not explicitly identify altered cell shape as a feature of reactive gliosis; section 3.2.3 links morphology changes to filament-network changes in astrocytoma cells, a different setting. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

GS can be upregulated by astrocytes and expressed by neurons in response to aging and AD.

“it has also been shown that GS can be upregulated by astrocytes [95] and expressed by neurons [24] in response to aging and AD.”

• cites [95] Fluteau A, Ince PG, Minett T, Matthews FE, Brayne C, Garwood CJ, et al. The nuclear retention of transcription factor FOXO3a correlates with a DNA damage response and increased glutamine synthetase expression by astrocytes suggesting a neuroprotective role in the ageing brain. Neurosci Lett. 2015; 609: 11– 7. 26455863 PMC4674771 sourcePartly supported

  The Results report that GS-positive astrocytes increased with measures of Alzheimer-type pathology, supporting the part attributed to this source. They also state that GS was not significantly related to age, so upregulation in response to aging is not established. The neuronal-expression claim has a separate citation and is not assessed here. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [24] Rose CF, Verkhratsky A, Parpura V. Astrocyte glutamine synthetase: pivotal in health and disease. Biochem Soc Trans. 2013; 41(6): 1518– 24. 24256247 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Under prolonged stress it can result in chronical inflammation.

“under prolonged stress it can result in chronical inflammation [20, 36, 105, 109].”

• cites [20] Filosa JA, Morrison HW, Iddings JA, Du W, Kim KJ. Beyond neurovascular coupling, role of astrocytes in the regulation of vascular tone. Neuroscience. 2016; 323(5): 96– 109. 25843438 PMC4592693 sourceCould not verify

  The Introduction section ‘Are microglia cells also components of the NVC response?’ discusses inflammatory responses to LPS and microglia–astrocyte signaling, but does not say that prolonged stress results in chronic inflammation. Searches for ‘prolonged stress chronic inflammation’ and ‘chronic inflammation stress’ found no passage making that connection; page numbers were unavailable in our copy. (LLM, conf=0.74)

  Experimental — accuracy not yet measured
• cites [36] Sullivan SM, Lee A, Björkman ST, Miller SM, Sullivan RKP, Poronnik P, et al. Cytoskeletal anchoring of GLAST determines susceptibility to brain damage: an identified role for GFAP. J Biol Chem. 2007; 282(40): 29414– 23. 17684014 sourceCould not verify

  The Discussion describes astrocyte and GLAST changes after hypoxia, not chronic inflammation caused by prolonged stress. Searches for prolonged stress and chronic inflammation, including inflammatory responses to sustained hypoxia, found no passage addressing that claim. (LLM, conf=0.72)

  Experimental — accuracy not yet measured
• cites [105] Greene C, Hanley N, Campbell M. Claudin‐5: gatekeeper of neurological function. Fluids Barriers CNS. 2019; 16: 3. 30691500 PMC6350359 sourcePartly supported

  The Psychiatric disorders section links stress to recruitment of peripheral immune signals and increased blood–brain barrier permeability. The Neuroinflammation section explains that loss of barrier integrity can lead to neuroinflammation, but the paper does not say that prolonged stress results in chronic inflammation. (LLM, conf=0.77)

  Experimental — accuracy not yet measured
• cites [109] Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009; 32: 638– 47. 19782411 PMC2787735 sourcePartly supported

  The section on potential detrimental effects of reactive astrocytes says context-dependent signaling events might lead to chronic inflammation. It does not identify prolonged stress alone as the cause; the proposed mechanism involves combinatorial signaling between cell types and can involve acute as well as chronic events. No page number is available in our copy. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Aβ and inflammation decrease GLAST expression and function, weaken glutamate clearance, and favor excitotoxicity.

“prior reports have shown that Aβ [113] and inflammation [96] decrease GLAST expression and function [114], weaken glutamate clearance [115, 116], and favor excitotoxicity [25, 28].”

• cites [113] Tong H, Zhang X, Meng X, Xu P, Zou X, Qu S. Amyloid‐beta peptide decreases expression and function of glutamate transporters in nervous system cells. Int J Biochem Cell Biol. 2017; 85: 75– 84. 28189841 sourceNot checked — no full text of the source
• cites [96] Takaki J, Fujimori K, Miura M, Suzuki T, Sekino Y, Sato K. L‐glutamate released from activated microglia downregulates astrocytic L‐glutamate transporter expression in neuroinflammation: the “collusion” hypothesis for increased extracellular L‐glutamate concentration in neuroinflammation. J Neuroinflammation. 2012; 9: 1– 17. 23259598 PMC3575281 sourceSupported
• cites [114] Ugbode C, Hu Y, Whalley B, Peers C, Rattray M, Dallas ML. Astrocytic transporters in Alzheimer's disease. Biochem J. 2017; 474(3): 333– 55. 28108584 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Atrophied astrocytes are characterized by decreased cell size and reduction of complexity.

“Atrophied astrocytes are characterized by decreased cell size and reduction of complexity [45, 46, 47].”

• cites [45] Hol EM, Pekny M. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol. 2015; 32: 121– 30. 25726916 sourceNot checked — no full text of the source
• cites [46] Lechuga‐Sancho AM, Arroba AI, Frago LM, García‐Cáceres C, Delgado‐Rubín De Célix A, Argente J, et al. Reduction in the number of astrocytes and their projections is associated with increased synaptic protein density in the hypothalamus of poorly controlled diabetic rats. Endocrinology. 2006; 147(11): 5314– 24. 16873533 sourceNot checked — no full text of the source
• cites [47] Verkhratsky A. Astroglial calcium signaling in aging and Alzheimer's disease. Cold Spring Harb Perspect Biol. 2019; 11(7): a035188. 31110130 PMC6601464 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Atrophied astrocytes fail to maintain the glutamate‐glutamine shuttle and display insufficient glutamate clearance because of reduced synaptic coverage, contributing to synaptic extinction and cognitive deficiency.

“previous reports have shown that atrophied astrocytes fail to maintain the glutamate‐glutamine shuttle [28, 47] and display insufficient glutamate clearance [43] because of reduced synaptic coverage [45, 46, 47], contributing to synaptic extinction and cognitive deficiency [43].”

• cites [28] Verkhratsky A, Ho MS, Vardjan N, Zorec R, Parpura V, Verkhratsky A. General pathophysiology of astroglia HHS public access. Adv Exp Med Biol. 2019; 1175: 149– 79. 31583588 PMC7188602 sourceCould not verify

  The sections on glutamine transporters and glutamate transporters describe the normal shuttle and the role of perisynaptic astrocyte processes in buffering glutamate (page unavailable). The passages retrieved for astrocytic atrophy and reduced synaptic coverage do not say that atrophied astrocytes fail to maintain the shuttle or establish the claimed consequences; the decisive portion may also be absent from our truncated copy. (LLM, conf=0.68)

  Experimental — accuracy not yet measured
• cites [47] Verkhratsky A. Astroglial calcium signaling in aging and Alzheimer's disease. Cold Spring Harb Perspect Biol. 2019; 11(7): a035188. 31110130 PMC6601464 sourcePartly supported

  The ‘Astroglia in Aging’ section links astrocytic atrophy and reduced glutamine synthetase expression to *possible* abnormalities in neurotransmission; it does not establish that atrophied astrocytes fail to maintain the glutamate–glutamine shuttle. The ‘Astrogliopathology in Alzheimer’s Disease’ section reports atrophic astrocytes with altered glutamate-transporter distribution, but does not establish the reduced synaptic coverage attributed to this source. The cited passages provide no page numbers. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites [43] Verkhratsky A, Ho MS, Vardjan N, Zorec R, Parpura V. General pathophysiology of astroglia. Adv Exp Med Biol. 2019; 1175: 149– 79. 31583588 PMC7188602 sourcePartly supported

  The “Astroglial Atrophy” section links astrodegeneration to impaired glutamate–glutamine shuttling. It separately describes insufficient glutamate clearance in amyotrophic lateral sclerosis and reduced synaptic coverage contributing to synaptic extinction and cognitive deficiency in Alzheimer’s disease. It does not say that reduced coverage causes the insufficient clearance. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [45] Hol EM, Pekny M. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol. 2015; 32: 121– 30. 25726916 sourceNot checked — no full text of the source
• cites [46] Lechuga‐Sancho AM, Arroba AI, Frago LM, García‐Cáceres C, Delgado‐Rubín De Célix A, Argente J, et al. Reduction in the number of astrocytes and their projections is associated with increased synaptic protein density in the hypothalamus of poorly controlled diabetic rats. Endocrinology. 2006; 147(11): 5314– 24. 16873533 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

GS decreases in aging, AD, and reactive astrocytes.

“It has been described that GS decreases in aging [47], AD [112], and reactive astrocytes [94].”

• cites [47] Verkhratsky A. Astroglial calcium signaling in aging and Alzheimer's disease. Cold Spring Harb Perspect Biol. 2019; 11(7): a035188. 31110130 PMC6601464 sourceCould not verify

  The citation [94] is attached specifically to the claim that GS decreases in reactive astrocytes. The ‘Astroglia in Aging’ section mentions an age-dependent decrease in GS expression, but does not link it to reactive astrocytes; the sections discussing astrogliosis do not report a GS decrease. The copy therefore does not verify the part attributed to this source. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [112] Walton HS, Dodd PR. Glutamate‐glutamine cycling in Alzheimer's disease. Neurochem Int. 2007; 50(7–8): 1052– 66. 17141374 sourceNot checked — no full text of the source
• cites [94] Ortinski PI, Dong J, Mungenast A, Yue C, Takano H, Watson DJ, et al. Selective induction of astrocytic gliosis generates deficits in neuronal inhibition. Nat Neurosci. 2010; 13(5): 584– 91. 20418874 PMC3225960 sourceSupported

May combine two claims.

APOEch displays the highest burden and broadest distribution of Aβ and the lowest levels of p‐tau among the studied conditions.

“APOEch displays the highest burden and broadest distribution of Aβ and the lowest levels of p‐tau among the studied conditions [65].”

• cites [65] Sepulveda‐Falla D, Sanchez JS, Almeida MC, Boassa D, Acosta‐Uribe J, Vila‐Castelar C, et al. Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia. Acta Neuropathol. 2022; 1: 1– 13. PMC9381462 35838824 sourcePartly supported

  The Results (Neuroimaging findings; page unavailable) report that the APOE3ch carrier’s Aβ PET burden remained higher than that of other PSEN1 E280A carriers. The Results (Neuropathological findings; page unavailable) describe widely distributed Aβ and unusually low tau pathology in some regions, but do not establish the broadest Aβ distribution or the lowest overall p-tau levels among the compared cases; they also report extensive p-tau pathology in other regions. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Fine‐tuned modification of astrocytic GFAP and vimentin expression is critical for the execution of the astrocyte reactive program.

“fine‐tuned modification of astrocytic GFAP and vimentin expression is critical for the execution of the astrocyte reactive program [28, 71, 91].”

• cites [28] Verkhratsky A, Ho MS, Vardjan N, Zorec R, Parpura V, Verkhratsky A. General pathophysiology of astroglia HHS public access. Adv Exp Med Biol. 2019; 1175: 149– 79. 31583588 PMC7188602 sourceSupported
• cites [71] Heneka MT, Sastre M, Dumitrescu‐Ozimek L, Dewachter I, Walter J, Klockgether T, et al. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation. 2005; 2: 1– 12. 16212664 PMC1274341 sourcePartly supported

  The Results and Discussion (page unavailable) associate increased astrocytic GFAP expression with activation in APP[V717I] mice. They do not address vimentin or establish that fine-tuned changes in either protein are critical for executing a reactive program. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [91] Hol EM, Capetanaki Y. Type III intermediate filaments desmin, glial fibrillary acidic protein (GFAP), vimentin, and peripherin. Cold Spring Harb Perspect Biol. 2017; 9(12): 1– 18. PMC5710105 29196434 sourcePartly supported

  Section 3.2.2 (page unavailable) says GFAP and vimentin increase during reactive gliosis and that deficiency in GFAP or both proteins weakens the response. It does not establish that fine-tuned changes in their expression are critical for executing the reactive program; the section says the precise contributions of the intermediate-filament proteins need further study. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Vimentin and GFAP link astrocyte structure and gliovascular function, and are associated with cytoplasmic proteins participating in signal transduction pathways.

“Vimentin and GFAP link astrocyte structure and gliovascular function [90, 92], and are associated with cytoplasmic proteins [92] participating in signal transduction pathways [44, 45, 106, 107].”

• cites [90] DeFelipe J, Alonso‐Nanclares L, Arellano JI. Microstructure of the neocortex: comparative aspects. J Neurocytol. 2002; 31: 299– 316. 12815249 sourceNot checked — no full text of the source
• cites [92] Middeldorp J, Hol EM. GFAP in health and disease. Prog Neurobiol. 2011; 93(3): 421– 43. 21219963 sourceNot checked — no full text of the source
• cites [44] Kamphuis W, Kooijman L, Orre M, Stassen O, Pekny M, Hol EM. GFAP and vimentin deficiency alters gene expression in astrocytes and microglia in wild‐type mice and changes the transcriptional response of reactive glia in mouse model for Alzheimer's disease. Glia. 2015; 63(6): 1036– 56. 25731615 sourceNot checked — no full text of the source
• cites [45] Hol EM, Pekny M. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol. 2015; 32: 121– 30. 25726916 sourceNot checked — no full text of the source
• cites [106] Nichols NR, Day JR, Laping NJ, Johnson SA, Finch CE. GFAP mRNA increases with age in rat and human brain. Neurobiol Aging. 1993; 14(5): 421– 9. 8247224 sourceNot checked — no full text of the source
• cites [107] Khakh BS, Sofroniew MV. Diversity of astrocyte functions and phenotypes in neural circuits. Nat Neurosci. 2015; 18(7): 942– 52. 26108722 PMC5258184 sourcePartly supported

  The 'Morphological complexity' section says GFAP is found in astrocytes’ major branches, supporting a limited link between GFAP and astrocyte structure. Our copy does not mention vimentin or establish that GFAP and vimentin link structure to gliovascular function or are associated with cytoplasmic proteins. The signal-transduction clause is attached to other citations, so it is not assessed against this source. (LLM, conf=0.80)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Hypertrophied astrocytes display thicker intermediate filament bundles, highly upregulate GFAP and are associated with neuroprotection and postlesion regeneration.

“hypertrophied astrocytes display thicker intermediate filament bundles, highly upregulate GFAP [45, 109] and are associated with neuroprotection and postlesion regeneration [28, 45, 46, 47].”

• cites [45] Hol EM, Pekny M. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol. 2015; 32: 121– 30. 25726916 sourceNot checked — no full text of the source
• cites [109] Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009; 32: 638– 47. 19782411 PMC2787735 sourcePartly supported

  The 'Defining reactive astrogliosis' section describes progressive cellular hypertrophy and changes in molecular expression, while 'Reactive astrogliosis and neural protection and repair' says reactive astrocytes can protect neural tissue and aid repair. The retrieved passages do not establish thicker intermediate-filament bundles or specifically high GFAP upregulation. They support repair after injury, but not a general association with postlesion axon regeneration; the discussion of scar formation notes that it may inhibit axon regeneration. Page numbers are unavailable in our copy. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [28] Verkhratsky A, Ho MS, Vardjan N, Zorec R, Parpura V, Verkhratsky A. General pathophysiology of astroglia HHS public access. Adv Exp Med Biol. 2019; 1175: 149– 79. 31583588 PMC7188602 sourcePartly supported

  The 'Major Findings from Transcriptional Studies' section says reactive astrocytes highly upregulate GFAP and other intermediate-filament genes, consistent with morphological changes. The available passages do not establish thicker filament bundles or associate hypertrophied astrocytes with postlesion regeneration; a cited study’s title instead says that preventing astrocytic-process hypertrophy improves post-traumatic regeneration. The GFAP section links impaired astrocyte reactivity to worsened neuropathology, offering indirect support for neuroprotection. Page numbers are unavailable in our copy. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites [46] Lechuga‐Sancho AM, Arroba AI, Frago LM, García‐Cáceres C, Delgado‐Rubín De Célix A, Argente J, et al. Reduction in the number of astrocytes and their projections is associated with increased synaptic protein density in the hypothalamus of poorly controlled diabetic rats. Endocrinology. 2006; 147(11): 5314– 24. 16873533 sourceNot checked — no full text of the source
• cites [47] Verkhratsky A. Astroglial calcium signaling in aging and Alzheimer's disease. Cold Spring Harb Perspect Biol. 2019; 11(7): a035188. 31110130 PMC6601464 sourcePartly supported

  The 'ASTROGLIOPATHOLOGY IN ALZHEIMER'S DISEASE' section links reactive astrocyte hypertrophy with increased GFAP and other intermediate filaments and describes a neuroprotective role, while noting that reactivity can also be neurotoxic. The 'ASTROGLIA IN AGING' section reports thicker astroglial processes, not specifically thicker intermediate-filament bundles. No passage found supports postlesion regeneration. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Under this context, astroglial death increases.

“Under this context, astroglial death increases [28, 47].”

• cites [28] Verkhratsky A, Ho MS, Vardjan N, Zorec R, Parpura V, Verkhratsky A. General pathophysiology of astroglia HHS public access. Adv Exp Med Biol. 2019; 1175: 149– 79. 31583588 PMC7188602 sourceCould not verify

  The overview says the review does not discuss astrogliopathology. A passage on reactive astrogliosis after injury mentions cell death but does not identify it as astroglial death; the passages found by searching for astroglial death and astrocyte apoptosis likewise do not report an increase in astroglial death. The cited copy therefore does not establish the claim, and the preceding context is not provided. (LLM, conf=0.72)

  Experimental — accuracy not yet measured
• cites [47] Verkhratsky A. Astroglial calcium signaling in aging and Alzheimer's disease. Cold Spring Harb Perspect Biol. 2019; 11(7): a035188. 31110130 PMC6601464 sourceCould not verify

  The ‘Astrogliopathology in Alzheimer’s Disease’ section describes astroglial atrophy and loss of function, but does not report an increase in astroglial death. The ‘Astroglia in Aging’ section says astrocyte numbers seem unaffected in physiological aging. Searches for astroglial death, apoptosis, and cell loss found no passage establishing the claimed increase; the citing sentence does not specify what ‘this context’ refers to. (LLM, conf=0.72)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Astrocytes and microglia are the main ApoE-producers in the brain.

“astrocytes and microglia are the main ApoE‐producers in the brain [64]”

• cites [64] Riddell DR, Zhou H, Atchison K, Warwick HK, Atkinson PJ, Jefferson J, et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci. 2008; 28(45): 11445– 53. 18987181 PMC6671315 sourcePartly supported

  The Introduction states that brain ApoE is produced by astrocytes, and the Results document ApoE secretion from primary astrocytes. The passages from our copy do not establish that microglia produce ApoE or that astrocytes and microglia together are its main producers in the brain. Page numbers were not available in the indexed passages. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

May combine two claims.

The subcellular localization of GLAST is typically perisynaptic, and it is highly mobile within the astrocyte membrane influenced by neuronal and glial activity.

“the subcellular localization of GLAST is typically perisynaptic, it is highly mobile within the astrocyte membrane influenced by neuronal and glial activity [120].”

• cites [120] Malik AR, Willnow TE. Excitatory amino acid transporters in physiology and disorders of the central nervous system. Int J Mol Sci. 2019; 20(22): 1– 37. PMC6888459 31726793 sourcePartly supported

  The Introduction identifies GLAST as EAAT1, and Section 3 describes EAAT1 as prominently perisynaptic. Section 6 says that EAAT2—not GLAST/EAAT1—is highly mobile on astrocyte surfaces, with mobility affected by neuronal and glial activity. The mobility portion therefore is not supported for GLAST. (LLM, conf=0.90)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Increased capillary densities have been documented in aged individuals and Alzheimer's disease (AD).

“reduced vascular diameters and increased capillary densities [123] have been documented in aged individuals and AD [124]”

• cites [123] Bennett RE, Robbins AB, Hu M, Cao X, Betensky RA, Clark T, et al. Tau induces blood vessel abnormalities and angiogenesis‐related gene expression in P301L transgenic mice and human Alzheimer's disease. Proc Natl Acad Sci U S A. 2018; 115(6): E1289– 98. 29358399 PMC5819390 sourcePartly supported

  The Results (Time Course of Blood Vessel Density Changes) document increased vessel density in 15-month-old tau-transgenic mice, not aged people. The Discussion says studies of capillary density in human AD are conflicting and suggests any increase may be transient, so the source does not establish increased capillary density in aged individuals with AD. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [124] Ashok BS, Ajith TA, Sivanesan S. Hypoxia‐inducible factors as neuroprotective agent in Alzheimer's disease. Clin Exp Pharmacol Physiol. 2017; 44: 327– 34. 28004401 sourceNot checked — no full text of the source

May combine two claims.

Astrocyte reactivity is tightly linked to endothelial, which are in turn associated with loss of vascular structural integrity and opening of the BBB.

“Astrocyte reactivity is tightly linked to endothelial [50], which are in turn associated with loss of vascular structural integrity and opening of the BBB [15, 28, 38, 45, 107, 109, 121].”

• cites [50] Osipova ED, Semyachkina‐Glushkovskaya OV, Morgun AV, Pisareva NV, Malinovskaya NA, Boitsova EB, et al. Gliotransmitters and cytokines in the control of blood‐brain barrier permeability. Rev Neurosci. 2018; 29(5): 567– 91. 29306934 sourceNot checked — no full text of the source
• cites [15] Verkhratsky A, Nedergaard M. Physiology of astroglia. Physiol Rev. 2018; 98(1): 239– 389. 29351512 PMC6050349 sourcePartly supported

  The Aquaporins section (page unavailable) describes direct interactions between astrocyte endfeet and endothelial cells, and the Definition and Overview section describes astrocytes mounting a reactive response. Neither passage says astrocyte reactivity is tightly linked to endothelial cells. The later claim about vascular integrity and BBB opening carries different citations and is not assessed here. (LLM, conf=0.77)

  Experimental — accuracy not yet measured
• cites [28] Verkhratsky A, Ho MS, Vardjan N, Zorec R, Parpura V, Verkhratsky A. General pathophysiology of astroglia HHS public access. Adv Exp Med Biol. 2019; 1175: 149– 79. 31583588 PMC7188602 sourcePartly supported

  The Aquaporins section (page unavailable) says astrocyte endfeet interact directly with endothelial cells, and the transcriptional-studies section describes reactive astrogliosis after injury. Neither passage establishes that astrocyte reactivity is tightly linked to endothelial cells. The vascular-integrity and BBB-opening clause is attributed to other citations, not this paper. (LLM, conf=0.78)

  Experimental — accuracy not yet measured
• cites [38] Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010; 119(1): 7– 35. 20012068 PMC2799634 sourceSupported
• cites [45] Hol EM, Pekny M. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol. 2015; 32: 121– 30. 25726916 sourceNot checked — no full text of the source
• cites [107] Khakh BS, Sofroniew MV. Diversity of astrocyte functions and phenotypes in neural circuits. Nat Neurosci. 2015; 18(7): 942– 52. 26108722 PMC5258184 sourceCould not verify

  The citation [50] is attached to the asserted link between astrocyte reactivity and endothelial cells, not to the later BBB claim. The section “Two functionally distinct categories of reactive astrocytes” describes proliferation of perivascular astrocytes after injury, but does not establish a tight link between astrocyte reactivity and endothelial cells. Searches for endothelial involvement and vascular integrity found no passage addressing that link; page numbers were unavailable in our copy. (LLM, conf=0.72)

  Experimental — accuracy not yet measured
• cites [109] Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009; 32: 638– 47. 19782411 PMC2787735 sourcePartly supported

  The section on ablation of scar-forming astrocytes reports that removing reactive astrocytes prevented blood–brain barrier repair, supporting a relationship between astrocyte reactivity and vascular-barrier function. Our copy does not establish the more specific claim that astrocyte reactivity is tightly linked to endothelial cells. The later claim about loss of vascular integrity has separate citations and is not attributed to this source. (LLM, conf=0.74)

  Experimental — accuracy not yet measured
• cites [121] Dudvarski Stankovic N, Teodorczyk M, Ploen R, Zipp F, Schmidt MHH. Microglia–blood vessel interactions: a double‐edged sword in brain pathologies. Acta Neuropathol. 2016; 131: 347– 63. 26711460 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Other genetic variants identified as modifiers or protective against familial Alzheimer's disease (FAD) delay Alzheimer's disease (AD) onset and are related to astrocyte genes, ubiquitin-proteasome function, and p-tau degradation.

“Other genetic variants that have also been identified as modifiers or protective against FAD, delay AD‐onset and are related to astrocyte genes, ubiquitin‐proteasome function, and p‐tau degradation [61, 126, 129]”

• cites [61] Lalli MA, Cox HC, Arcila ML, Cadavid L, Moreno S, Garcia G, et al. Origin of the PSEN1 E280A mutation causing early‐onset Alzheimer's disease. Alzheimers Dement. 2014; 10(5): S277– S283.e10. 24239249 PMC4019728 sourceCould not verify

  The Discussion (page unavailable) says that future ancestry analysis may reveal additional variants influencing disease, but it does not identify protective modifiers or report delayed onset. Searches for astrocyte genes, ubiquitin-proteasome function, p-tau degradation, and age-at-onset modifiers found no passage addressing those claims. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [126] Vélez JI, Rivera D, Mastronardi CA, Patel HR, Tobón C, Villegas A, et al. A mutation in DAOA modifies the age of onset in PSEN1 E280A Alzheimer's disease. Neural Plast. 2016; 2016: 9760314. 26949549 PMC4753688 sourcePartly supported

  The Results (section 3.2; page unavailable) identify a DAOA variant associated with age of onset in people with PSEN1 E280A familial Alzheimer’s disease, and the Discussion (section 4; page unavailable) links EXOC2 to astrocyte research. The paper does not establish that these variants delay onset or protect against disease, and the passages found do not connect them to ubiquitin-proteasome function or p-tau degradation. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [129] Sepulveda‐Falla D, Chavez‐Gutierrez L, Portelius E, Vélez JI, Dujardin S, Barrera‐Ocampo A, et al. A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer's disease. Acta Neuropathol. 2021; 141(2): 217– 33. 33319314 PMC7847436 sourcePartly supported

  The Results and Discussion link genetic variants in PSEN1 E280A familial Alzheimer’s disease to age of onset, ubiquitin–proteasome function, and p-tau degradation. Our copy does not link the identified variants to astrocyte genes, so that part of the sentence is not supported by this source. The passages provided have no page numbers. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Reduced vascular diameters have been documented in aged individuals and Alzheimer's disease (AD).

“reduced vascular diameters and increased capillary densities [123] have been documented in aged individuals and AD [124]”

• cites [123] Bennett RE, Robbins AB, Hu M, Cao X, Betensky RA, Clark T, et al. Tau induces blood vessel abnormalities and angiogenesis‐related gene expression in P301L transgenic mice and human Alzheimer's disease. Proc Natl Acad Sci U S A. 2018; 115(6): E1289– 98. 29358399 PMC5819390 sourcePartly supported

  The Results section reports reduced blood-vessel diameters in aged Tg4510 mice compared with controls. The Discussion describes collapsed capillaries in human AD, but does not establish reduced vascular diameters in aged individuals or people with AD. The claim extends a mouse finding to humans. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [124] Ashok BS, Ajith TA, Sivanesan S. Hypoxia‐inducible factors as neuroprotective agent in Alzheimer's disease. Clin Exp Pharmacol Physiol. 2017; 44: 327– 34. 28004401 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

ApoE is involved in the modulation of glutamate transport and metabolism.

“ApoE is also involved in the modulation of glutamate transport and metabolism [128]”

• cites [128] Dumanis SB, DiBattista AM, Miessau M, Moussa CEH, Rebeck GW. APOE genotype affects the pre‐synaptic compartment of glutamatergic nerve terminals. J Neurochem. 2013; 124(1): 4– 14. 22862561 PMC3509249 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Neuroinflammation induces claudin-5 redistribution favoring hypervascularization and blood-brain barrier (BBB) leakage.

“neuroinflammation induces its redistribution favoring hypervascularization and BBB leakage [126]”

• cites [126] Vélez JI, Rivera D, Mastronardi CA, Patel HR, Tobón C, Villegas A, et al. A mutation in DAOA modifies the age of onset in PSEN1 E280A Alzheimer's disease. Neural Plast. 2016; 2016: 9760314. 26949549 PMC4753688 sourceCould not verify

  The Discussion (page unavailable) mentions astrocytes’ contribution to neuroinflammation in Alzheimer’s disease, but does not address claudin-5 redistribution, hypervascularization, or BBB leakage. Searches for those terms and for vascular permeability and tight junctions found no passage supporting the claimed mechanism. (LLM, conf=0.75)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Potentially claudin-5-positive extracellular vesicles increase near the vessels of the frontal cortex in a manner that differentiates sporadic Alzheimer's disease (SAD) from familial Alzheimer's disease (FAD).

“we had previously shown that potentially claudin‐5‐positive extracellular vesicles increase near the vessels of the frontal cortex in a manner that differentiates SAD from FAD [73]”

• cites [73] Villar‐Vesga J, Henao‐Restrepo J, Voshart DC, Aguillón D, Villegas A, Castaño D, et al. Differential profile of systemic extracellular vesicles from sporadic and familiar Alzheimer's disease leads to neuroglial and endothelial cell degeneration. Front Aging Neurosci. 2020; 12: 587989. 33281599 PMC7705379 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Altered expression of glutamine synthetase (GS) is associated with changes in endothelial cell migration and vessel sprouting.

“altered expression of GS is associated with changes in endothelial cell migration and vessel sprouting [122]”

• cites [122] Eelen G, Dubois C, Cantelmo AR, Goveia J, Brüning U, DeRan M, et al. Role of glutamine synthetase in angiogenesis beyond glutamine synthesis. Nature. 2018; 561(7721): 63– 9. 30158707 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Previous reports show reduced perivascular AQP4 in E280A carriers.

“previous reports of reduced AQP4 perivascular in E280A carriers [66]”

• cites [66] Littau JL, Velilla L, Hase Y, Villalba‐Moreno ND, Hagel C, Drexler D, et al. Evidence of beta amyloid independent small vessel disease in familial Alzheimer's disease. Brain Pathol. 2022; e13097. 35695802 PMC9616091 sourcePartly supported

  The Results (Astrocytosis and astrocyte end feet pathology in PSEN1 FAD) report reduced perivascular AQP4 reactivity in dilated versus non-dilated vessels within PSEN1 p.Glu280Ala FAD cases. They also report no difference in perivascular AQP4 reactivity between the FAD, SAD and CADASIL groups. The claim omits the vessel-specific condition and could imply a general reduction in E280A carriers. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim. May combine two claims.

ApoE binding to heparan sulfate proteoglycans (HSPGs) has been suggested to promote amyloid-beta (Aβ) aggregation and neuronal uptake of extracellular p-tau.

“ApoE binding to heparan sulfate proteoglycans (HSPGs) has been suggested to promote Aβ aggregation and neuronal uptake of extracellular p‐tau [62]”

• cites [62] Arboleda‐Velasquez JF, Lopera F, O'Hare M, Delgado‐Tirado S, Marino C, Chmielewska N, et al. Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019; 25(11): 1680– 3. 31686034 PMC6898984 sourcePartly supported

  The Abstract (page unavailable) says HSPGs have been suggested to promote Aβ aggregation and neuronal uptake of extracellular tau, and that ApoE binding may be necessary for some of these effects. It does not specify phosphorylated tau (p-tau) or say that ApoE binding promotes both effects. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Endothelial tight junction claudin-5 influences the functional stability of the cerebral vasculature.

“both endothelial tight junction claudin‐5 and vimentin influence the functional stability of the cerebral vasculature [11, 105]”

• cites [11] Dave JM, Bayless KJ. Vimentin as an integral regulator of cell adhesion and endothelial sprouting. Microcirculation. 2014; 21: 333– 44. 24387004 sourceNot checked — no full text of the source
• cites [105] Greene C, Hanley N, Campbell M. Claudin‐5: gatekeeper of neurological function. Fluids Barriers CNS. 2019; 16: 3. 30691500 PMC6350359 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Ablation of reactive astrocytes prevents the reconstruction of injured blood-brain barrier (BBB).

“ablation of reactive astrocytes prevents the reconstruction of injured BBB [28, 38, 45]”

• cites [28] Verkhratsky A, Ho MS, Vardjan N, Zorec R, Parpura V, Verkhratsky A. General pathophysiology of astroglia HHS public access. Adv Exp Med Biol. 2019; 1175: 149– 79. 31583588 PMC7188602 sourceCould not verify

  The overview (section I; page unavailable) says astrocytes control the blood-brain barrier and mount a defensive response, while the transcriptional-studies section describes reactive astrocytes after injury. Neither passage addresses whether ablating reactive astrocytes prevents reconstruction of an injured barrier. Searches for astrocyte ablation and blood-brain barrier repair found no decisive passage in our copy, whose end may be missing. (LLM, conf=0.68)

  Experimental — accuracy not yet measured
• cites [38] Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010; 119(1): 7– 35. 20012068 PMC2799634 sourceSupported
• cites [45] Hol EM, Pekny M. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol. 2015; 32: 121– 30. 25726916 sourceNot checked — no full text of the source

Classified as probably not a substantial claim. May combine two claims.

Both proinflammatory molecules and glutamate have been broadly shown to impair the structure and function of brain endothelium.

“Both proinflammatory molecules and glutamate have been broadly shown to impair the structure and function of brain endothelium [50, 51].”

• cites [50] Osipova ED, Semyachkina‐Glushkovskaya OV, Morgun AV, Pisareva NV, Malinovskaya NA, Boitsova EB, et al. Gliotransmitters and cytokines in the control of blood‐brain barrier permeability. Rev Neurosci. 2018; 29(5): 567– 91. 29306934 sourceNot checked — no full text of the source
• cites [51] Vazana U, Veksler R, Pell GS, Prager O, Fassler M, Chassidim Y, et al. Glutamate‐mediated blood–brain barrier opening: implications for neuroprotection and drug delivery. J Neurosci. 2016; 36(29): 7727– 39. 27445149 PMC4951577 sourcePartly supported

  The section “Excessive glutamate release enhances vascular permeability” reports that glutamate increased brain-vessel permeability and describes earlier findings of altered endothelial tight-junction proteins. The cited paper does not show that proinflammatory molecules impair brain endothelium; its Discussion instead describes neuroinflammation as associated with increased endothelial permeability. Page numbers are unavailable in our copy. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

The familial Alzheimer's disease (E280A) group average age of onset was 46.7 years.

“| | Average | | 46.7 | 60.1 | 13.4 | 4.2 | | | | | |”

Probably not a substantial claim: may not pass S3 (load-bearing).

The familial Alzheimer's disease (E280A) group average disease duration was 13.4 years.

“| | Average | | 46.7 | 60.1 | 13.4 | 4.2 | | | | | |”

Probably not a substantial claim: may not pass S3 (load-bearing).

The sporadic Alzheimer's disease group average age at death was 86.9 years.

“| | Average | | 75.4 | 86.9 | 11.4 | 3.8 | | | | | |”

Probably not a substantial claim: may not pass S3 (load-bearing).

The control group average PI was 6.7.

“| | Average | | | 67.4 | | 6.7 | | | | | |”

Probably not a substantial claim: may not pass S3 (load-bearing).

The sporadic Alzheimer's disease group average PI was 3.8.

“| | Average | | 75.4 | 86.9 | 11.4 | 3.8 | | | | | |”

Probably not a substantial claim: may not pass S3 (load-bearing).

The control group average age at death was 67.4 years.

“| | Average | | | 67.4 | | 6.7 | | | | | |”

Probably not a substantial claim: may not pass S3 (load-bearing).

The APOEch (E280A) subject was female.

“| APOEch | APOEch (E280A) | F | 72 a | 77 | 5 a | 3.2 | C | 6 | 5 | A3, B3, C3 | Hypertension, dyslipidemia, metastatic melanoma |”

Probably not a substantial claim: may not pass S3 (load-bearing).

The APOEch (E280A) subject had a Braak stage of 6.

“| APOEch | APOEch (E280A) | F | 72 a | 77 | 5 a | 3.2 | C | 6 | 5 | A3, B3, C3 | Hypertension, dyslipidemia, metastatic melanoma |”

Probably not a substantial claim: may not pass S3 (load-bearing).

The APOEch (E280A) subject had an NIA-AA score of A3, B3, C3.

“| APOEch | APOEch (E280A) | F | 72 a | 77 | 5 a | 3.2 | C | 6 | 5 | A3, B3, C3 | Hypertension, dyslipidemia, metastatic melanoma |”

May combine two claims.

Astrodegeneration and vascular deterioration are prominent in SAD.

“demonstrate that, while astrodegeneration and vascular deterioration are prominent in SAD, FAD is characterized by hyperreactive‐like glia, and APOEch displays the mildest astrocytic and vascular alterations despite having the highest burden of Aβ.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The APOEch (E280A) subject had an age of death of 77 years.

“| APOEch | APOEch (E280A) | F | 72 a | 77 | 5 a | 3.2 | C | 6 | 5 | A3, B3, C3 | Hypertension, dyslipidemia, metastatic melanoma |”

Probably not a substantial claim: may not pass S3 (load-bearing).

The APOEch (E280A) subject had a PI of 3.2.

“| APOEch | APOEch (E280A) | F | 72 a | 77 | 5 a | 3.2 | C | 6 | 5 | A3, B3, C3 | Hypertension, dyslipidemia, metastatic melanoma |”

Probably not a substantial claim: may not pass S3 (load-bearing).

The familial Alzheimer's disease (E280A) group average PI was 4.2.

“| | Average | | 46.7 | 60.1 | 13.4 | 4.2 | | | | | |”

Probably not a substantial claim: may not pass S3 (load-bearing).

The sporadic Alzheimer's disease group average disease duration was 11.4 years.

“| | Average | | 75.4 | 86.9 | 11.4 | 3.8 | | | | | |”

Probably not a substantial claim: may not pass S3 (load-bearing).

The familial Alzheimer's disease (E280A) group average age at death was 60.1 years.

“| | Average | | 46.7 | 60.1 | 13.4 | 4.2 | | | | | |”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The APOEch (E280A) subject had comorbidities of hypertension, dyslipidemia, and metastatic melanoma.

“| APOEch | APOEch (E280A) | F | 72 a | 77 | 5 a | 3.2 | C | 6 | 5 | A3, B3, C3 | Hypertension, dyslipidemia, metastatic melanoma |”

Probably not a substantial claim: may not pass S3 (load-bearing).

The APOEch (E280A) subject had a disease duration of 5 years.

“| APOEch | APOEch (E280A) | F | 72 a | 77 | 5 a | 3.2 | C | 6 | 5 | A3, B3, C3 | Hypertension, dyslipidemia, metastatic melanoma |”

Probably not a substantial claim: may not pass S3 (load-bearing).

The sporadic Alzheimer's disease group average age of onset was 75.4 years.

“| | Average | | 75.4 | 86.9 | 11.4 | 3.8 | | | | | |”

Probably not a substantial claim: may not pass S3 (load-bearing).

The APOEch (E280A) subject had an age of onset of 72 years.

“| APOEch | APOEch (E280A) | F | 72 a | 77 | 5 a | 3.2 | C | 6 | 5 | A3, B3, C3 | Hypertension, dyslipidemia, metastatic melanoma |”

Probably not a substantial claim: may not pass S3 (load-bearing).

The APOEch (E280A) subject had a Thal phase of 5.

“| APOEch | APOEch (E280A) | F | 72 a | 77 | 5 a | 3.2 | C | 6 | 5 | A3, B3, C3 | Hypertension, dyslipidemia, metastatic melanoma |”

Probably not a substantial claim: may not pass S3 (load-bearing).

The APOEch (E280A) subject had a CERAD score of C.

“| APOEch | APOEch (E280A) | F | 72 a | 77 | 5 a | 3.2 | C | 6 | 5 | A3, B3, C3 | Hypertension, dyslipidemia, metastatic melanoma |”

May combine two claims.

The cell density decrease in layers I-III in SAD and FAD was caused by the loss of both nonpyramidal-like and pyramidal-like cells, while the density of pyramidal-like cells in APOEch was comparable to that in CNT.

“While the cell density decrease in layers I–III in SAD and FAD was caused by the loss of both nonpyramidal‐like and pyramidal‐like cells, the density of pyramidal‐like cells in APOEch was comparable to that in CNT (Figure 1G).”

May combine two claims.

IBA1 in layer III was higher in FAD than in SAD, while APOEch showed similar levels to CNT.

“In particular, IBA1 in layer III was higher in FAD than in SAD, while APOEch showed similar levels to CNT (Figure 3C).”

• AssumptionRests on an assumption: A depth beyond 300 μm approximately corresponds to layer III of the gray matter.

May combine two claims.

Cell density was significantly decreased in the upper layers in SAD and FAD, while only SAD displayed a reduction in cell density in the lower layers.

“Consistently with the presence of Aβ and p‐tau, the number of cells above and below 1 mm depth—which approximately corresponds to neuronal layers I–III and IV–VI of the GM, respectively [90]—revealed a significant cell density decrease in the upper layers in SAD and FAD, while only SAD displayed a reduction in cell density in the lower layers (Figure 1E,F).”

May combine two claims.

Vimentin is typically observed throughout the gray matter in the vasculature of CNT, is less frequent in SAD and FAD, and is moderately common in APOEch.

“although vimentin was typically observed throughout the GM in the vasculature of CNT, it was less frequent in SAD and FAD and moderately common in APOEch (Figure 8B).”

• AssumptionRests on an assumption: The single APOEch case studied is representative of APOEch homozygotes.

May combine two claims.

The number of vessels per analyzed field of view in layer III of the gray matter is significantly increased in SAD and to a lesser extent in FAD, while APOEch remains similar to CNT.

“we found that the number of vessels per analyzed field of view significantly increased in SAD and to a lesser extent in FAD, while APOEch remained similar to CNT (Figure 7A,B).”

• AssumptionRests on an assumption: The single APOEch case studied is representative of APOEch homozygotes.

May combine two claims.

Almost all microvascular structures are claudin-5-positive in SAD and FAD, while numerous capillaries show no staining in CNT and APOEch.

“Whereas almost all of the microvascular structures were claudin‐5‐positive in SAD and FAD, numerous capillaries did not show any staining in CNT and APOEch.”

• AssumptionRests on an assumption: The single APOEch case studied is representative of APOEch homozygotes.

May combine two claims.

In the perivasculature of FAD, the proportion of double-positive GFAP-GLAST decreased and there was a trend toward lower GS.

“In contrast, a decrease in the proportion of double‐positive GFAP‐GLAST and a trend toward lower GS were identified in the perivasculature of FAD.”

May combine two claims.

The total surface of capillaries in layer III of the gray matter is greater only in SAD, while FAD and APOEch do not differ from CNT.

“the total surface of the capillaries was only greater in SAD, while FAD and APOEch did not differ from CNT.”

• AssumptionRests on an assumption: The single APOEch case studied is representative of APOEch homozygotes.

May combine two claims.

Cellular deterioration of frontal cortical layers I-III is associated with Aβ and p‐tau in SAD and FAD but not in APOEch.

“Cellular deterioration of frontal cortical layers I–III is associated with Aβ and p‐tau in SAD and FAD but not in APOEch”

May combine two claims.

In CNT, GS astrocytes were present from layer III onward, whereas in SAD and FAD they increased from layer I.

“As previously described [102], GS astrocytes were present from layer III onward in CNT, whereas in SAD and FAD increased from layer I (Figure 4C).”

• cites [102] Papageorgiou IE, Valous NA, Lahrmann B, Janova H, Klaft ZJ, Koch A, et al. Astrocytic glutamine synthetase is expressed in the neuronal somatic layers and down‐regulated proportionally to neuronal loss in the human epileptic hippocampus. Glia. 2018; 66(5): 920– 33. 29350438 sourceNot checked — no full text of the source

• AssumptionRests on an assumption: The CNT samples are free of Alzheimer's disease pathology.

May combine two claims.

There is no difference in capillary volume per field between SAD and FAD, and APOEch is close to the mean in FAD.

“However, no differences were found between SAD and FAD, and APOEch was close to the mean in FAD (Figure 7D).”

• AssumptionRests on an assumption: The single APOEch case studied is representative of APOEch homozygotes.

May combine two claims.

The number of UEA I fragments and the percentage of gaps area in layer III of the gray matter are increased in SAD but not in FAD or APOEch.

“Similarly, the number of UEA I fragments and the percentage of gaps area increased in SAD but not in FAD or APOEch.”

May combine two claims.

There are no differences between SAD and FAD in claudin-5 optical density or extravascular staining.

“no differences between SAD and FAD were found in either optical density or extravascular staining (Figure 8C).”

May combine two claims.

CNT astrocytes exhibited the most radial configuration, followed by FAD and SAD, while APOEch presented the most stretched configuration.

“In addition, CNT astrocytes exhibited the most radial configuration (convex hull circularity), followed by FAD and SAD, while APOEch presented the most stretched.”

May combine two claims.

The microglia of APOEch presented the smallest and simplest morphology, and exhibited less reactive-like characteristics in the frontal cortex than in other brain regions.

“Intriguingly, the microglia of APOEch presented the smallest and simplest morphology, and exhibited less reactive‐like characteristics in the frontal cortex than in other brain regions (Figure S4C,D).”

May combine two claims.

The percentage of GFAP area was highest in FAD, followed by SAD, and lowest in APOEch, which was strikingly similar to CNT.

“On the one hand, the percentage of GFAP area was the highest in FAD, followed by SAD, and the lowest in APOEch which was strikingly similar to CNT (Figure 2D).”

May combine two claims.

GLAST exhibited a diffuse expression pattern from layer III onward in CNT, while in SAD and FAD it was homogenously distributed throughout all upper layers with a distinctive aggregated pattern in layer III that was also detected in APOEch.

“Comparably, GLAST exhibited a diffuse expression pattern from layer III onward in CNT, while in SAD and FAD, it was homogenously distributed throughout all of the upper layers presenting a distinctive aggregated pattern in layer III that was also detected in APOEch.”

• AssumptionRests on an assumption: The single APOEch sample (one case, three replicates) is representative of APOE3 Christchurch homozygotes.
• AssumptionRests on an assumption: The CNT samples are free of Alzheimer's disease pathology.

May combine two claims.

The percentage of GFAP area in FAD was meaningfully greater than in CNT and SAD, while APOEch displayed comparable values to those of CNT.

“The percentage of GFAP area in FAD was meaningfully greater than in CNT and SAD, while APOEch displayed comparable values to those of CNT.”

May combine two claims.

APOEch presented the highest cell density among the E280A group in layers I-III, and did not show remarkable differences within the group in the lower layers.

“APOEch presented the highest cell density among the E280A group in layers I–III, and did not show remarkable differences within the group in the lower layers.”